the printed Meeting Program

Transcription

MECHANISMS OF EFFICACY IN CANCER IMMUNOTHERAPY
14 CIMT
Annual Meeting
th
PROGRAM GUIDE
MAY 10–12, 2016
CIMT - Association for Cancer Immunotherapy
meeting.cimt.eu
cimt.eu
PROGRAM GUIDE 2016
14TH ANNUAL MEETING
MAY 10–12, 2016
Rheingoldhalle Congress Center
Mainz, Germany
CIMT Summary
CIMT Summary
ANNUAL MEETING 2016
SUMMARY
CIMT 2016
PROGRAM
ABOUT CIMT
OVERVIEW
Floor Plan, Program 22–23
Introduction, Who We Are,
Program Committee 05–06
INFORMATION
PROGRAM SCHEDULE
Day 1–3, 25–36
Sponsors & Partners, Websites 09–12
SPEAKERS
PLENARY SPEAKERS
Biography 13–17
INDUSTRY SATELLITE SYMPOSIA SPEAKERS
Biography 19-20
INFORMATION
INDUSTRY EXHIBITORS
39-41
POSTER PRESENTATIONS
42-43
IMPRINT
68
2
ABSTRACTS
ABSTRACT LIST
Therapeutic Vaccination 45–48
Cellular Therapy 49–52
Immunomonitoring 53–54
New Targets & New Leads 55–57
Improving Immunity 58–59
Tumor Biology and Interaction with
the Immune System 60–64
CIMT 2016
CIMT 2016
INTRODUCTION
MECHANISMS OF EFFICACY
IN CANCER IMMUNOTHERAPY
DEAR
COLLEAGUES,
MEMBERS
AND FRIENDS
EXECUTIVE BOARD:
Christoph Huber, Chair
Mainz, Germany
Peter Johnson
Southampton, UK
Ulrich Kalinke
Hanover, Germany
Cornelis Melief
Welcome to the 14th Annual Meeting of
the Association for Cancer Immunotherapy!
Leiden, The Netherlands
Hans-Georg Rammensee
After a surge of recent approvals and promising research studies,
Tübingen, Germany
we now see immunotherapies included in the standard of care.
Cancer patients are benefiting from immune checkpoint inhibitors,
Carl Figdor
adoptive cell therapy using engineered T cells is moving through
Nijmegen, The Netherlands
clinical testing, and highly individualized immunotherapies show
the potential to address the complex and ever-changing tumor environments. To optimize clinical benefits for each and every patient,
potent combination and individualized therapies promise another
Dolores J. Schendel
Munich, Germany
breakthrough in cancer treatment.
As we see therapeutic effects, we now face the challenge of elu-
Axel Hoos
cidating the mechanisms of efficacy for these therapeutic break
Collegeville, USA
throughs in order to carefully integrate them into standard treatment protocols.
In this year`s meeting, you will hear updates of the state-of-thefield, from regulatory aspects to new targets and drug modalities to
Özlem Türeci
Mainz, Germany
increased understanding of immunotherapeutic efficacy. We have
put together an exciting scientific program with outstanding speakers who kindly accepted our invitation to share their knowledge.
As always, CIMT will provide you with the opportunity to meet and
interact with friends and colleagues in person. Early-career scien-
Sebastian Kreiter
Mainz, Germany
Chairman of CIMT Management
Board
tists will have the opportunity to present their work in poster and
oral presentations. For the first time, a Meet the Editor session will
enable direct interaction with the editors of prestigious journals in
a panel discussion.
A dedicated Voice of the Patients session will reflect the view of our
most important partners in the quest for optimized cancer immunotherapies.
Thank you for joining us.
Yours sincerely,
The CIMT Executive Board
4
5
THE ASSOCIATION
WHO WE ARE
2016 PROGRAM COMMITTEE:
Sebastian Kreiter
TRON – Translational Oncology at the
University Medical Center of the Johannes
Gutenberg University Mainz
(Mainz, Germany)
Sine Reker Hadrup
Technical University of Denmark
(Copenhagen, Denmark)
Sjoerd van der Burg
Leiden University Medical Center
(Leiden, The Netherlands)
Rienk Offringa
German Cancer Research Center (DKFZ)
(Heidelberg, Germany)
The Association for Cancer Immunotherapy (CIMT) was
founded in 2002 as an information and education platform
for the emerging field of immunological cancer therapy.
Physicians and researchers from different fields of clinical
Mustafa Diken
TRON – Translational Oncology at the
University Medical Center of the Johannes
Gutenberg University Mainz
(Mainz, Germany)
and theoretical medicine were the founding members of
the association. CIMT has since become the leading Euro-
Andreas Diefenbach
pean communication platform for all aspects of science and
Research Center Immunology (FZI) at the
Johannes Gutenberg University Mainz
(Mainz, Germany)
translation in the field of cancer immunotherapy. CIMT operates as an independent non-profit organization in Mainz,
Germany, and is financed by donations, sponsoring and
Michael Kalos
congress fees.
Eli Lilly (New York, USA)
Our Goals
Harpreet Singh
CIMT promotes the development of cancer immunothera-
Immatics Biotechnologies
(Tübingen, Germany)
pies by
*offering a platform for knowledge exchange between scientists of all faculties interested in cancer immunotherapy. CIMT connects industry-based scientists, academic
Ci3 PROJECT:
EDUCATION AND NETWORKING PLATFORM
FOR INDIVIDUALIZED IMMUNE INTERVENTION
CIMT is supported by a research grant from the
German Ministry for Education and Research
(BMBF) as part of the Rhein-Main Cluster for
Individualized Immune Intervention (Ci3). The
aim of the project is to advance CIMT as a European education and networking platform for
individualized immune intervention medicine
that offers the opportunity for information exchange of international top level scientists from
academia, industry and regulatory bodies in
Mainz and at meetings worldwide. The project
will allow to continue and expand the activities
of the CIMT Regulatory Research Group and to
embark on new activities, such as workshops
on technology commercialization (CIMT
Endeavour), the co-organization of scientific
sessions with international partners (CIMT
Satellites) and patient communication (“Voice
of the Patients”).
The following sessions and workshops during the CIMT 2016 Annual
Meeting are supported by the German Ministry for Education and
Research (BMBF):
TUESDAY, MAY 10
17:30–18:00
Voice of the Patients
WEDNESDAY, MAY 11
08:00– 12:00
CIMT Endeavour
08:00– 09:30
Plenary Session 3 on Therapeutic Vaccination
10:00–11:30
Short Talk Session I on Cellular Therapy
14:00–15:30
Plenary Session 4 on Cellular Therapy
THURSDAY, MAY 12
08:30– 10:00
Plenary Session 5 on Novel Technologies for Immune Assessment
10:30–11:45
Short Talk Session V on Therapeutic Vaccination
11:45–13:00
Short Talk Session VI on Immunomonitoring
14:30–16:00
Plenary Session 6 on Antibodies
scientists, regulatory authorities and physicians alike.
*cooperating internationally with partners in related consortia, regulatory agencies, journals, academic institutions and companies.
*initiating working groups that actively accelerate the development in the field.
*organizing annual meetings, advanced education seminars, symposia, workshops, and by publishing guidelines
and textbooks.
6
SUPPORTED BY:
CIMT 2016
ANNUAL MEETING
SPONSORS &
PARTNERS
CIMT 2016 is made possible by the generous
support from our sponsors and partners:
DNA BARCODE DEXTRAMERS ALLOW SCREENING OF 1000+ T CELL
SPECIFICITIES IN A SINGLE SAMPLE
DNA BARCODE DEXTRAMERS
– BIOMARKERS AND TOOL
Platinum
FOR EPITOPE DISCOVERY
FZI
ForschungsZentrum
Immunologie
Gold
NEO-EPITOPE DISCOVERY BY MASSIVE MULTIPLEXING
The DNA barcoding approach allows hundreds of potential neo-epitopes
to be screened in a single cell sample (e.g. blood, TILs), leading to the
identification of the few real and biologically relevant neo-epitopes.
Silver
MULTIPLEXING IN CLINICAL TRIALS
The high sensitivity and specificity of the DNA barcoding approach enables
a comprehensive analysis of the cellular response to a given treatment,
providing valuable information about mechanism-of-action (MoA) and
epitope spreading in e.g. adoptive T cell therapy or checkpoint inhibitor
treatment.
Bronze
Get more information about DNA barcode Dextramers on
www.immudex.com
Sponsors of CIP
Partners
9
CIMT 2016
ANNUAL MEETING
WEBSITES
visit our websites
www.cimt.eu & www.meeting.cimt.eu
follow us on twitter
www.twitter.com/C_IMT
#cimt2016
find us on facebook
www.facebook.com/cimtmainz
follow us on Linkedin
www.linkedin.com/company/cimt
Smartphone Schedule
Get the CIMT online schedule
for your smartphone
schedule.cimt.eu
Online Abstracts
Get the CIMT online abstracts
(iPad App, eBook, PDF)
abstracts.cimt.eu
COPYRIGHT AND IMAGE RIGHTS AT CIMT 2016
1.Posters, graphics, lectures are usually protected by international copyright laws. Each lecturer warrants that he holds
the rights of use to the items used during his lecture (texts, photographs, graphics).
YOU SEE A MOUSE.
WE SEE A CURE FOR CANCER.
2.It is not permitted without express prior authorization by the author(s) to take pictures of posters, graphics, people,
etc., and to transfer these pictures to third parties via social media (facebook, twitter,….) or webpages. The person
taking the pictures must be able to provide proof of such authorization by the author(s) (e.g. author’s mail). Protected
material may only be used if the author(s) is mentioned by name.
3.Each participant agrees to indemnify CIMT against any claims for damages by third parties arising from the infringement of any rights by the participant.
4.Each participant agrees to allow CIMT to take pictures of him/her during the event, and he/she agrees to the use of
such pictures for CIMT advertising purposes (Internet,…) and press releases.
Accelerate your oncology research with the JAX™ NSG mouse – the most immunodeficient strain available. See how the NSG
is the obvious choice for your cancer xenograft modelling, immuno-oncology studies, stem cell research and challenging blood
tumours. For more information or to enquire about model evaluation, visit us at www.criver.com/nsg.
Charles River is the exclusive distributor of JAX™ Mice in Europe.
CIMT Speakers
ANNUAL MEETING
joy
we deliver the
of health
We are working to
ensure people remain
healthy and vibrant.
Visit us at
MerckGroup.com
PLENARY
SPEAKERS
Gwendolyn Binder-Scholl
Vincenzo Bronte
Adaptimmune
New York, USA
University of Verona
Verona, Italy
Gwendolyn Binder-Scholl is the founding member and
Chief Technology Officer of Adaptimmune, responsible
for strategic leadership of platform and pipeline research,
and manufacturing sciences. Her original training is in
viral neuro-immunology at Johns Hopkins University,
Baltimore. Since 2002, she has worked in translational
research, cell manufacturing, regulatory affairs, clinical development and translational medicine / correlative research in the field of cell and gene therapy, with
a research focus in T-cell immunotherapy for HIV and
oncology. She previously held positions at the University of Pennsylvania as the Director of Translational
Research Operations, under Carl June, where she oversaw the opening of 5 new INDs for novel gene therapy
products. Prior to the University of Pennsylvania, Gwendolyn Binder-Scholl was the Director of Scientific Affairs
at Virxsys Corporation, where she was involved in the
translational and regulatory aspects of the first human
application of a lentiviral vector.
Vincenzo Bronte is currently Head of the Immunology Section at the Department of Medicine of Verona
University and Head of the U.O.C of Immunology at the
Policlinico G. B. Rossi Hospital. He is Full Professor
of Immunology at the University of Verona. Vincenzo
Bronte’s major achievement has been the definition
and characterization of myeloid-derived suppressor
cells (MDSCs), whose negative influence on antitumor immunity represents an obstacle to a successful
immunotherapy of cancer. Current projects in the laboratory are further exploring the cellular and molecular mechanisms underlying tumor-induced immune
dysfunctions, with the attempt to define novel drugs
and approaches targeting tumor microenvironment, to
be used alone or in combination with either active or
passive immunotherapy strategies.
Chiara Bonini
Rony Dahan
Fondazione San Raffaele del Monte Tabor
Milan, Italy
The Rockefeller University
New York, USA
Chiara Bonini is Deputy Director of the Research Division of Immunology, Infectious Diseases and Transplantation and Head of the Experimental Hematology
Unit at the San Raffaele Scientific Institute in Milan,
Italy. Her lab is developing innovative approaches to
cancer immunotherapy with genetically modified lymphocytes. She has extensive experience in transplant
immunobiology, gene therapy, and cellular therapy.
Chiara Bonini is recipient of the Young Investigator
Award, American Society of Gene Therapy 2005, the
Team Science Recognition Award, International Society
for Biological Therapy of Cancer 2010, the Van Bekkum
Award, European Society of Bone Marrow Transplantation (EBMT) 2012, and of the Van Rood Award, Immunobiology Working Party EBMT 2013, among others.
She is currently chairman of the Cellular Therapy and
Immunobiology Working party of EBMT.
Rony Dahan is a CRI Irvington postdoctoral fellow in
the Laboratory of Molecular Genetics and Immunology at the Rockefeller University. Rony Dahan holds
a PhD in molecular immunology from the TechnionIsrael Institute of Technology (2011). He is studying the
involvement of Fcγ Receptor pathways in the modes of
action of immunomodulatory therapeutic antibodies.
His studies include elucidating the contributions of
FcγR-engagements for the anti-tumor activity of both
antagonistic antibodies targeting the PD-1/PD-L1 axis
and agonistic human anti-CD40 antibodies. A recent
direction of his research is focused on activity of
human IgG-FcγRs interaction using FcγR humanized
mouse models.
13
CIMT Speakers
14
CIMT Speakers
Giuliano Elia
Robert Hawkins
Kin-Ming Lo
Mikael Pittet
Philochem
Otelfingen, Switzerland
The University of Manchester and The Christie Hospital
Manchester, United Kingdom
EMD-Serono (Merck KgaA)
Billerica, USA
Harvard Medical School
Cambridge, USA
Giuliano Elia obtained his PhD in chemistry at the
University of Rome La Sapienza. He worked at CNR's
Institute of Experimental Medicine in Rome for a
number of years before moving to Switzerland, where
he spent time as a visiting scientist at the Friedrich
Miescher Institute in Basel. Later, he moved to ETH in
Zurich, where he worked in the group of Prof. Dario
Neri and as Group Leader of the Proteomic Unit of
the Institute of Pharmaceutical Sciences. From 2006
to 2013, Giuliano Elia was Director of the Mass Spectrometry and Proteomics Resource of the Conway
Institute, University College Dublin and, from 2009,
Coordinator of Post-graduate Education of the same
institute. In March 2013, he returned to Switzerland
where he took over the position of Senior Director
Product Development at Philochem AG.
Robert Hawkins is Cancer Research UK Professor
of Medical Oncology at the University of Manchester and Christie Hospital. His main clinical interests
are in renal/adrenal cancers, focusing on immunotherapy. Robert Hawkins leads a group undertaking
translational research into immunotherapy of cancer
with a focus on adoptive cell therapy. In addition to
pre-clinical research, he has developed a GMP cell
therapy unit to provide clinical grade cell manufacturing – this operates as a joint University Facility
and a commercial spinout company (Cellular Therapeutics Ltd). He is a founder and CEO of Cellular
Therapeutics Ltd that is the first company to produce
commercial adoptive cell therapy products for cancer
treatment. He is/has been the coordinator of several
major European Union consortia in this field.
Kin-Ming Lo is Senior Director, Immuno-Oncology
Translational Innovation Platform, EMD Serono (Merck
KGaA). After holding positions at Abbot Lab and Fuji
ImmunoPharmaceuticals (former Lexigen) when it
was founded in 1992, he became VP of Research at
Lexigen when the company was acquired by EMD in
1999. He remained as VP of Research at EMD Lexigen
for ten years, during which he was responsible for the
research and development of the immunocytokine and
Fc-X technologies. When EMD Serono was formed, he
first served as Global Head of Antibody Technologies
and later joined the Immuno-Oncology Translational
Innovation Platform as Head of Immuno-Technology
in late 2012. He is an inventor on over 30 patents and
patent applications on antibodies and antibody fusion
proteins, including two EMD Serono Immuno-Oncology drug candidates, NHS-IL12 and anti-PD-L1/TGF
Trap, currently in clinical trials.
Mikael Pittet completed his PhD at the Ludwig Institute for Cancer Research in Lausanne, Switzerland
in 2001 and trained as a postdoctoral fellow at Massachusetts General Hospital (MGH), Dana Farber
Cancer Institute and Harvard Medical School (HMS)
in Boston, USA. Mikael Pittet began his independent research in 2007, currently serves as an Associate
Professor at HMS, and is faculty member of the Center
for Systems Biology at MGH. His research program
focuses on discovering previously unrecognized
tumor-host cell interactions and identifying aspects
of immune cell dynamics in disease that could establish new paradigms for translational efforts. Work
from the Pittet lab combines several approaches,
including in-vivo imaging, to study the maturational
pathways, trafficking, and functions of immune cell
types found in tumors and other diseased tissues.
Wolf Hervé Fridman
Darrell Irvine
Cornelis Melief
George Prendergast
University Paris-Descartes
Paris, Frankreich
Massachusetts Institute of Technology
Cambridge, USA
Leiden University Medical Center and
ISA Pharmaceuticals
Leiden, The Netherlands
Lankenau Institute for Medical Research
Wynnewood, USA
Wolf H. Fridman is a Professor of Immunology at the
Paris Descartes University Medical School in Paris. He
founded the Cordeliers Research Centre, a joint research
structure between INSERM, University Paris Descartes,
and University Pierre et Marie Curie. Wolf Fridman’s
research interests have been focused around the role
of the immune system in controlling human tumors
and the biological functions of Fc receptors. His main
contributions in cancer immunology stand up to 1969
when he published, with François Kourilsky, the first
demonstration of an immune response of the patient
to his own cancer, in acute leukemia. He then focused
on the analysis of the tumor microenvironment. His
publications with Jérôme Galon and Franck Pagès have
changed the paradigm of host/cancer interactions by
demonstrating that the “immune contexture” is the
major prognostic factor for human cancers.
Darrell Irvine is a Professor at the Massachusetts Institute of Technology and an Investigator of the Howard
Hughes Medical Institute. His research is focused on the
application of engineering tools to problems in cellular
immunology and the development of new materials for
vaccine and drug delivery. Current efforts are focused
on problems related to vaccine development for HIV and
and immunotherapy of cancer. Darrell Irvine’s work
has been recognized by numerous awards, including
a Beckman Young Investigator award, an NSF CAREER
award, selection for Technology Review’s ‘TR35’, election as a Fellow of the Biomedical Engineering Society,
election as a fellow of the American Institute for Medical and Biological Engineering, and appointment as an
investigator of the Howard Hughes Medical Institute.
He is the author of over 100 publications, reviews, and
book chapters and an inventor on numerous patents.
Sine Reker Hadrup
Cornelis Melief is emeritus professor of internal medicine specialized in “immunohematology” at Leiden
University. Since 2011, he has been emeritus professor at LUMC and Chief Scientific Officer of ISA Pharmaceuticals, a biotech company specializing in the
development of synthetic vaccines. He received his
M.D. and Ph.D. degree from the University of Amsterdam. Cornelis Melief has made many contributions to
basic immunology, including work in mouse models,
and clinical immunology. In recent years, effective
immunotherapy of tumors with synthetic long peptides
(SLP) has been developed in mouse and rabbit models. This has led to the implementation of clinical trials
in patients with cancer of viral and non-viral origin.
Recently, clinical effectiveness was shown in the treatment of patients with established lesions caused by
high risk human papilloma virus type 16 (HPV 16).
George Prendergast began his career on the faculty of The
Wistar Institute in Philadelphia and later directed a drug
discovery team at the DuPont Pharmaceuticals Company.
In 2002, he moved his groups to the Lankenau Institute
for Medical Research to create a unique ‘acapreneurial’
organization that integrates biotech start-up companies
with non-profit laboratory and clinical groups to speed
translation of discoveries to clinic. From this platform,
George Prendergast and his colleagues pioneered the preclinical discovery, validation and clinical translation of
indoximod and the first true enzymatic small molecule
inhibitors of IDO1. More recently, his team has shown how
IDO1 acts to sustain inflammatory processes needed for
angiogenesis. This line of work has dovetailed with studies of the IDO2 discovered at Lankenau, which will illustrate critical newly defined roles for this gene in pancreatic cancer and autoimmune disease. Since 2010, George
Prendergast has been Editor-in-Chief of Cancer Research.
Carl June
Paul Parren
Ellen Puré
Technical University of Denmark
Copenhagen, Denmark
University of Pennsylvania
Philadelphia, USA
Genmab
Utrecht, The Netherlands
University of Pennsylvania
Philadelphia, USA
Sine Reker Hadrup is an expert in T-cell detection by use of MHC multimers. She has focused for
many years on the development of multiplex strategies for T-cell detection to comprehensively assess
antigen-specific tumor reactivity among T cells in
cancer patients. Sine Reker Hadrup is the head of a
research group at the Technical University of Denmark in Herlev. Novel technologies developed in her
research group allow the simultaneous detection
of more than 1,000 different antigen-responding
T cells. Currently, the research group focuses on
using this technology to unravel the immune reactivity towards cancer associate neo- and shared
epitopes, as well as understanding the influence of
cancer therapy on the immune recognition fingerprint in individual patients.
Carl June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine. He is currently Director of the Center for
Cellular Immunotherapies at the University of Pennsylvania, and is an Investigator of the Abramson Family
Cancer Research Institute. He is a graduate of the Naval
Academy in Annapolis, and Baylor College of Medicine
in Houston. Carl June maintains a research laboratory
that studies various mechanisms of lymphocyte activation that relate to immune tolerance and adoptive immunotherapy for cancer and chronic infection. In 2011,
his research team published findings detailing a new
therapy in which patients with refractory and relapsed
chronic lymphocytic leukemia were treated with genetically engineered versions of their own T cells. The treatment is now also used with promising results to treat
children with refractory acute lymphoblastic leukemia.
He has published more than 350 manuscripts and is the
recipient of numerous prizes and honors.
Paul Parren holds a PhD in molecular immunology from
the University of Amsterdam. He was an Associate Professor at The Scripps Research Institute in La Jolla, California, where he studied human antibodies in protection and vaccines against viral infections. In 2002, Paul
Parren joined Genmab where he serves in the position
of Senior Vice President and Scientific Director. He is
also a Professor of Molecular Immunology at the Leiden University Medical Center in Leiden and an Adjunct
Professor of Translational Cancer Research at the University of Southern Denmark. In 2016, he was elected
President of The Antibody Society, a non-profit trade
organization representing the interests of antibody
engineering and therapeutics. Paul Parren is an inventor and developer of several therapeutic antibodies, e.g.
ofatumumab (ARZERRA, approved in 62 countries),
and the DuoBody and HexaBody technologies that enable the development of bispecific and effector-function
enhanced antibodies.
Ellen Puré is the Grace Lansing Lambert Professor of
Biomedical Science and Chair of the Department of
Biomedical Sciences at the University of Pennsylvania
School of Veterinary Medicine. Ellen Puré received her
Baccalaureate degree from Washington University in
St. Louis, and her doctorate at the University of Texas
Southwestern Medical School and then joined the Faculty at the Rockefeller University. In 1992, Ellen Puré
moved to Philadelphia where she was on the Faculty
of the Wistar Institute until moving to the University
of Pennsylvania in 2013. Her research focuses on the
cellular and molecular basis of inflammation and fibrosis. A major focus of her laboratory’s work is to define
the role of stromal cells, extracellular matrix (ECM) and
matrix remodeling in cancer initiation, progression and
metastasis, and to develop novel therapeutic approaches
that target the stromal compartment of tumors to use
in combination with immune based and other conventional therapies that target malignant cells.
15
CIMT Speakers
16
CIMT Speakers
Laszlo Radvanyi
Gerold Schuler
Timothy Tree
EMD-Serono (Merck KgaA)
Billerica, USA
Universitätsklinikum Erlangen
Erlangen, Germany
King's College London
London, United Kingdom
Laszlo Radvanyi is Senior Vice President (SVP), Global
Head of Immuno-Oncology R&D at EMD Serono (Merck
KgaA, Darmstadt Germany) where he leads pre-clinical
and early clinical translational research on tumor immunotherapy combinations and biomarker discovery at the
company’s USA (Billerica, MA) and German (Darmstadt)
R&D sites. Previously, Dr. Radvanyi was a Professor in the
Department of Melanoma Medical Oncology at the University of Texas, M.D. Anderson Cancer Center in Houston
and then joined Lion Biotechnologies developing T-cell
therapies for solid tumors and leading pre-clinical and process development work resulting in two key IND filings
for TIL therapy trials currently underway in metastatic
melanoma, head and neck cancer, and cervical cancer. He
also performed basic and translational research identifying biomarkers in T-cell therapy, improving the anti-tumor
function of expanded T cells, and developing improved
manufacturing methods for T-cell therapy.
Gerold Schuler is Professor of Dermatology at FriedrichAlexander University Erlangen-Nuremberg and head of
the Dept. of Dermatology at University Hospital Erlangen. His main scientific contributions have been i)
discovery of the maturation of dendritic cells; ii) identification of GM-CSF as the key cytokine for myeloid
dendritic cell differentiation which resulted in the first
reproducible generation of dendritic cells from hematopoietic precursors in the mouse and subsequently the
development of the current “gold standard” of human
dendritic cell generation from monocytes using GM-CSF
+ IL-4 or IL-13; and iii) identification of CD4+CD25+
regulatory T cells in humans. Gerold Schuler and his
research team explore the adoptive transfer of ex vivo
generated DC to vaccinate against cancer, and they have
established a translational unit including a GMP laboratory with manufacturing license for dendritic cells and
mRNA for phase I to phase III trials.
Timothy Tree is a specialist in human T-cell immunology with particular expertise in analysing the
function of regulatory T cells in human health and
disease. Timothy Tree studied Biochemistry at Imperial College London and then completed a PhD at the
same institute funded by the World Health Organization investigating the role of the immune system
in the pathology associated with infection with the
filarial nematode Onchocerca volvulus, which leads
to river blindness. His current research interests are
focused on understanding the role of pathogenic
and regulatory T cells in human health, disease
and transplantation. These studies have led to the
identification of several novel populations of antigen
specific regulatory T cells as well us uncovering an
underlying defect in regulatory T cell function in
individuals with type 1 diabetes.
Matthias Renner
Hergen Spits
Paul-Ehrlich-Institute
Langen, Germany
AIMM Therapeutics
Amsterdam, The Netherlands
Matthias Renner is Scientific Assessor in the Department
of Medical Biotechnology at the Paul-Ehrlich-Institute,
Germany, where he is involved in the evaluation of clinical
trial applications and in national scientific advice procedures for ATMPs. He serves also as expert to the European
Medicines Agency (EMA) for the assessment of marketing
authorization applications and scientific advices. Matthias
Renner has been a member of the Committee for Advanced
Therapies (CAT) Gene Therapy Working Party since 2010
and its vice chair since 2011. He is doing research on different aspects of cell and gene therapy and lentivirus biology.
Prior to joining PEI in 2009, he served as Department Head
for Vector Development and Preclinical Models at Austrianova, Vienna, where he was responsible for developing the
company´s gene therapy products. Since 2007, he has also
been affiliated with the University of Veterinary Medicine
Vienna, serving as group leader at the Institute of Virology
until 2008 and as senior lecturer in virology.
Hergen Spits is a professor of cell biology at the University of Amsterdam, where he leads a research program
on auto immune- and inflammatory diseases. He is
also CSO of AIMM therapeutics which develops human
monoclonal antibodies. Hergen Spits has made several
contributions to the field of human lymphocytes and
was the first to describe the phenomenon of redirected
killing by human T cells using anti CD3 antibodies.
More recent contributions include the first description
of Th22 cells and the discovery of human Lymphoid
Tissue inducer cell and various other human Innate
Lymphoid cell (ILC) subsets. While studying the mechanisms of development of human antibody-producing
B cells, his lab also invented an innovative technology
to immortalize human and non-human antibody-producing B cells which was used to establish a number
of broadly reacting highly neutralizing virus specific
antibodies, some of which are in clinical development.
Doris Schmitt
Per thor Straten
PATH
Radolfzell, Germany
University of Copenhagen
Copenhagen, Denmark
Doris Schmitt is a communications consultant advising companies in management and sales. A breast
cancer diagnosis and cancer in the family made her
realize how important it is to be informed about one’s
own disease and treatment options. In order to gather
information on the latest study results in the mamma
carcinoma and non-small-cell lung carcinoma field,
she regularly visits cancer congresses at home and
abroad. As a volunteer, she supports the executive
board of PATH, a breast cancer biobank where tissue taken from breast cancer patients is frozen and
stored free of charge in order to make it available to
research. In her publications, seminars, and lectures,
Doris Schmitt educates physicians, pharmacists, caregivers and patients on the importance of an equal
footing between physician and patient.
Per thor Straten is Professor at the Department of
Immunology and Microbiology of the University of
Copenhagen and Director at the Centre for Cancer
Immunotherapy (CCIT), Department of Hematology, at the University Hospital Herlev in Denmark.
Research programs at CCIT include the characterization of tumor antigens, clinical trials using adoptive
cell transfer (ACT) of T cells by in- vitro expansion
of tumor infiltrating lymphocytes (TIL), genetic
engineering of T cells for ACT aiming at improved
homing to - and functionality at - the tumor site.
Moreover, a recent direction is focused on exercise
as an immune modulator to control tumor growth
and incidence. Per thor Straten is a graduate of the
University of Copenhagen and The Open University
in Milton Keynes, United Kingdom. He is author/coauthor of more than 130 articles and patents in the
area of tumor immunology and immunotherapy.
IMMUNO-ONCOLOGY
Activating and directing the immune system to fight cancer
Revealing the Intricacies of
IMMUNO-ONCOLOGY
AstraZeneca is committed to advance the science
of IO combination therapy to deliver life-changing
medicines to patients most in need:
► Immunotherapy + Immunotherapy combination
► Immunotherapy + Chemotherapy combination
► Immunotherapy + Small Molecule combination
For more information, please visit
https://www.azimmuno-oncology.com/
CIMT Speakers
ANNUAL MEETING
A clinician, a scientist, a pathologist:
realising the promise of cancer immunotherapy
Satellite symposium sponsored by
Wednesday 11 May 2016
13.00–14.00
Rheingoldhalle Congress Center
Mainz, Germany
John B. Haanen
Kenneth Bloom
Netherlands Cancer Institute
Amsterdam, The Netherlands
Human Longevity, Inc.
San Diego, USA
John B. Haanen is Head of the Division of Medical
Oncology and Staff Scientist in the Division of Immunology at the Netherlands Cancer Institute. He is also
Professor of Translational Immunotherapy of Cancer
at Leiden University Medical Centre. John Haanen
received his medical degree from the University
of Leiden, then completed a PhD on human CD4+
helper T cells at the Department of Immunohematology and the Blood Bank of the Leiden University
Medical Centre and the DNAX Research Institute in
California, USA. He then trained in internal medicine
at Leiden University Medical Centre and at Bronovo
Hospital in The Hague, the Netherlands. His research
focuses on the translation of novel immunotherapy
strategies into the clinical practice, especially adoptive cell transfer programs and immune checkpoint
blockade. His clinical medical oncology practice
is focused on melanoma and renal cell carcinoma
patients.
Programme
Chair: Kenneth Bloom, California, USA
Ignacio Duran
13.00–13.05 Welcome and introduction
Kenneth Bloom, California, USA
Hospital Universitario Virgen del Rocio
Seville, Spain
13.05–13.15 Cancer immunotherapy: so far, so good?
Ignacio Duran, Seville, Spain
13.15–13.25 Modulating the tumour microenvironment: the future of cancer immunotherapy
John Haanen, Amsterdam, The Netherlands
13.25–13.35 Personalising cancer immunotherapy: beyond morphology
13.35–13.55 Panel discussion
All faculty
13.55–14.00 Summary and close
This presentation is not intended for physicians practising in the USA
INDUSTRY SATELLITE
SYMPOSIA SPEAKERS
NP/aPDL1/1604/0016
Roche-sponsored satellite symposium at the 14th Cancer Immunotherapy (CIMT) 2016 Annual Meeting
Ignacio Durán, M.D., Ph.D., is the Chief of Section
and Coordinator of the Urogenital Tumors Programs
at Hospital Universitario Virgen del Rocio (Seville.
Spain). He earned his M.D. in 1997 at the Universidad de Salamanca in Salamanca, Spain and his Ph.D.
in 2005 at the Universidad Complutense in Madrid,
Spain, with highest commendation. He trained in
Medical Oncology at the Hospital Universitario Son
Dureta in Palma de Mallorca, Spain and completed
his Fellowship in Drug Development at the Princess Margaret Hospital in Toronto, Canada between
2004-2007. Throughout his career, Dr. Duran has
spent significant time in distinguished national and
international investigational centers such as the
headquarters of the CSIC at the Universidad de Salamanca in Salamanca, Spain, Catholic University of
the Sacred Heart in Rome, Italy, Centre Hospitalier
Universitaire in Nantes, France, and Memorial Sloan
Kettering Cancer Center in New York City.
19
CIMT Speakers
Satellite symposium sponsored by
Certainly we cannot treat all
tumor types. But we are broadening
the horizon of cancer treatment.
Stephan Grabbe
Thomas Tüting
University Medical Center Mainz
Mainz, Germany
University Hospital Magdeburg
Magdeburg, Germany
Stephan Grabbe is Director and Chairman of the Department of Dermatology at the University Medical Center
Mainz, Germany. He studied medicine at the University
of Münster, Germany, and graduated with a Ph.D. in
dermatology. From 1989-1992, he was a Postdoctoral
Research Fellow at Harvard Medical School and Massachusetts General Hospital in Boston, and then became
Resident and Research Fellow at the University of Münster. After several years at the Universities of Münster
and Essen, he moved to his current position in Mainz.
Stephan Grabbe received numerous awards and honors, including a “Heisenberg” fellowship of the German Research Society. In his research, Stephan Grabbe
focuses on morphodynamics of the interaction between
dendritic cells and T cells, the role of b2 integrins in
antigen presentation as well as tumor immunotherapy
with dendritic cells and nanoparticles.
Thomas Tüting is Professor and Chairman of Dermatology at the University Hospital Magdeburg. In his
former position as Associate Professor of Experimental Dermatology and Head of Dermato-Oncology at the
University Hospital Bonn, Thomas Tüting pioneered
the establishment of novel genetic mouse model
systems that combine experimental tools of tumor
immunology and tumor biology to adequately portray
clinical situations observed in melanoma patients for
the preclinical development of novel combinatorial T
cell immunotherapies. An important finding was that
simultaneous triggering of endosomal and cytosolic
antiviral pattern recognition receptors with synthetic
oligonucleotides that activate the type I IFN system
supports T-cell effector functions in the tumor microenvironment and promotes tumor cell death. Using
adoptive T-cell transfer approaches, his group discovered that progressively growing autochthonous melanomas can resist cytotoxic T-cell responses directed
against melanocytic differentiation antigens through
reversible dedifferentiation in an inflammatory microenvironment. Non-genetic, inflammation-induced
phenotypic plasticity of melanoma and immune cells
may represent a more general mechanism how melanomas and other tumor entities resist various forms of
cytotoxic therapies.
Ralf G. Meyer
St.-Johannes-Hospital Dortmund
Dortmund, Germany
Ralf G. Meyer is Head of the Department of Internal
Medicine at the St.-Johannes-Hospital in Dortmund,
Germany. In his doctoral thesis in Immunology at the
group of Diethard Gemsa, Marburg as well as in the
laboratory of J. J. Oppenheim at the National Cancer
Institute, he focused on the role of chemokines in Influenza A-infections. Between 1996 and 2002, he worked
at the department of Internal Medicine at the Johannes
Gutenberg-University Mainz, Germany, and specialized in hematology. In Mainz, he focused his research
on immune-response analyses in the research group of
Thomas Woelfel. During his tenure at the hematology
department, he focused his research interest on allogeneic stem cell transplantation and founded his own
research group in 2007 in addition to his clinical work
as a hemato-/ oncologist at the university hospital. Ralf
Meyer and his team focused on allo-immune responses
and the role of antigen-presenting cells in GvHD. In 2013,
he was promoted to head the hematopoietic stem cell
transplantation program at the 3rd Medical Department
in Mainz.
20
Immuno - Oncology by Bristol-Myers Squibb
2016
2015
2011
immunooncology.com
ONCDE15PR02443-01
CIMT Program
CIMT Program
Session overview
FLOOR PLAN & PROGRAM
OVERVIEW
DAY 1 - MAY 10
08:00 - 08:30
REGISTRATION
PLENARY SESSION 3
Congress Hall
Therapeutic Vaccination
08:30 - 09:00
Meeting Location
DAY 2 - MAY 11
Congress Hall
WELCOME ADDRESS
Congress Hall
10:00 - 10:30
10:30 - 11:00
CIMT
ENDEAVOUR
Watford
Room
09:00 - 09:30
09:30 - 10:00
DAY 3 - MAY 12
Congress Hall
COFFEE BREAK
PLENARY SESSION 1
SHORT TALK S
ESSIONS I, II, III
Tumor Microenvironment
Gutenberg A & B;
Congress Hall
Congress Hall
PLENARY SESSION 5
Novel Technologies for Immune Assessment
COFFEE BREAK
SHORT TALK
SESSIONS IV, V,
VI, VII
11:00 - 11:30
REGULATORY
RESEARCH SESSION
Congress Hall
Gutenberg A & B
11:30 - 12:00
West Foyer
Congress Hall
Gutenberg B
Gutenberg A
North Foyer
LUNCH
LUNCH
12:00 - 12:30
INDUSTRY
SATELLITE I
12:30 - 13:00
Bristol-Myers Squibb
Congress Hall
INDUSTRY
SATELLITE II
13:00 - 13:30
Rhine Foyer
13:30 - 14:00
Roche
Congress Hall
PLENARY SESSION 2
Improving Immunity
Upper Floor
14:00 - 14:30
Congress Hall
14:30 - 15:00
MEET THE EDITORS
Congress Hall
PLENARY SESSION 4
Cellular Therapy
PLENARY SESSION 6
Congress Hall
Antibodies
Registration
Lower Floor
East Foyer
Dijon Room
Watford Room
15:00 - 15:30
POSTER SESSION I AND
COFFEE BREAK
15:30 - 16:00
Foyer
16:00 - 16:30
16:30 - 17:00
Congress Hall
POSTER
SESSION II
AND
COFFEE
BREAK
EU CONSORTIA SESSION
Gutenberg A
Foyer
17:00 - 17:30
17:30 - 18:00
18:00 - 18:30
VOICE OF THE PATIENTS
Congress Hall
KEYNOTE LECTURE
Congress Hall
18:30 - 19:00
CIMT MEMBERS MEETING
Dijon Room
19:00 - 19:30
19:30 - 20:00
20:00 - 24:00
22
LUNCH
SOCIAL EVENT & AWARDS CEREMONY
Rhine Foyer
CIMT Program
Glioma Actively Personalized Vaccine Consortium
GAPVAC presents:
PRELIMINARY DATA ON SAFETY, FEASIBILITY AND
BIOLOGICAL ACTIVITY
Glioblastoma (GB) is the most common type of malignant brain tumor with very poor prognosis and a
high unmet medical need. The Glioma Actively Personalized Vaccine Consortium (GAPVAC) is a European consortium aiming to take personalized cancer immunotherapy to the next level by generating
individual biomarker-tailored therapeutic vaccines for patients with glioblastoma.
Each patient participating in the GAPVAC-101
phase I clinical trial receives two actively personalized vaccines (named APVAC). APVAC1 consists
of patient-tailored tumor-associated HLA-peptides
selected from a pre-manufactured warehouse of
approx. 60 antigens shared by a number of glioblastoma patients. APVAC2 vaccine targets patient tumor-specific mutations or over-presented
peptides and is de novo manufactured for every
patient.
ANNUAL MEETING
PROGRAM
SCHEDULE
CIMT 2016
Day 1 – May 10
08:00-09:30
Foyer
REGISTRATION
Sign-in and badge pickup
09:30-10:00
Congress Hall
Five European authorities have approved the GAPVAC-101 phase I study and patients are enrolled in six
centers across Europe. As of today 13 patients have been enrolled to the trial from which ten have already
been treated with at least one APVAC.
After the successful transfer of this novel and ambitious concept of actively personalized cancer
immunotherapy into the clinic, first data with regard to safety, feasibility and biological activity will
be presented at this year´s CIMT Annual Meeting.
CIMT is a consortium partner and the primary dissemination platform for results of the GAPVAC
trial. If you want to learn more about the project, please visit the following presentations as well as
the GAPVAC webpage www.gapvac.eu:
�Poster 40: GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide vaccination trial in
patients with newly diagnosed glioblastoma
10:00-11:30
Congress Hall
Immatics biotechnologies GmbH (Coordinator)
Heidelberg University Hospital (Chief Investigator)
BioNTech (Vice Coordinator)
Geneva University Hospital (Co-Chief Investigator)
University of Tübingen, Germany
Barcelona Vall d´Hebron University Hospital
BCN Peptides S.A., Spain
Leiden University Medical Centre, Netherlands
Technion Israel Institute of Technology
Copenhagen Herlev Hospital, Denmark
CIMT
University of Southampton, UK
Christoph Huber, CIMT
PLENARY SESSION 1
Tumor Microenvironment
Chairs: Michele Maio (Siena, Italy), Rienk Offringa (Heidelberg, Germany)
10:00-10:30
Mikael Pittet, Harvard Medical School
"Cancer-host cell interactions: analysis in context"
10:30-11:00
Ellen Puré, University of Pennsylvania
“The functional heterogeneity of tumor stroma: implications for modulating
antitumor immunity and enhancing immunotherapy”
11:00-11:30
Vincenzo Bronte, University of Verona
"Immune suppressive and immune stimulating monocytes in cancer"
� Talk on May 11, 4 p.m.: GAPVAC: First results from a personalized peptide vaccination study in glioblastoma
Thirteen institutions from academia and industry, supported by the European Commission’s 7th framework
program (FP7) 2012, are joint in GAPVAC to realize this highly innovative project:
WELCOME ADDRESS
11:30 -13:00
Foyer
LUNCH
Lunch boxes and drinks
University of California San Francisco (UCSF)
25
CIMT Program
CIMT Program
Day 1 – May 10
12:00 -13:00
Congress Hall
Day 1 – May 10
INDUSTRY SATELLITE I
organized by:
12:00-12:20
Thomas Tüting, University Hospital Magdeburg
"Introducing new horizons in cancer immunotherapy"
12:20-12:40
Ralf Meyer, St. Johannes Hospital Dortmund
"Immunotherapeutic approaches in lymphoma treatment"
12:40 -13:00
Stephan Grabbe, University Medical Center Mainz
"The next chapter in I-O: combination strategies for the treatment of malignant
melanoma"
Congress Hall
organized by:
13:30 -14:00
Hergen Spits, Amsterdam Medical Center
“B cell responses in cancer immunotherapy”
14:00-14:30
George Prendergast, Lankenau Institute for Medical Research
"IDO pathways in cancer therapy"
14:30 -15:00
Per thor Straten, University of Copenhagen
"Suppression of tumor growth and incidence by voluntary exercise"
Foyer
15:00-17:30
"Clinical studies and patient advocates"
Chair: Eva Winkler (NTC, Heidelberg)
18:00-19:00
Congress Hall
Doris Schmitt, PATH
"How can patient experts support treatment protocols and informed consent?"
KEYNOTE ADDRESS
Chair: Christoph Huber (Mainz, Germany)
Wolf Hervé Fridman, Centre de Recherche des Cordeliers
"The diversity of immune microenvironments in human cancers"
Improving Immunity
Chairs: Hansjoerg Schild (Mainz, Germany), Andreas Diefenbach (Mainz, Germany)
VOICE OF THE PATIENTS
PLENARY SESSION 2
15:00 -15:30
Congress Hall
Chair: Dirk Jäger (Heidelberg, Germany)
13:30 -15:00
17:30 -18:00
"Immuno-Oncology: Transforming the future and raising the bar in cancer treatment”
COFFEE BREAK
Coffee and snacks
Foyer
POSTER SESSION I
SEE WHAT INNOVATIONS IN IMMUNO-ONCOLOGY
COULD MEAN FOR YOUR PATIENTS
Our research and development team takes a broad and integrated approach and develops new
immunotherapy-based treatments that target cancer. This approach involves leveraging a robust and
diverse pipeline of molecules that target the tumor and the immunosuppressive microenvironment, and
developing rational combination strategies with an emerging internal pipeline of molecules that modulate
T cell function. We are also investigating novel approaches to redirect activated T cells to tumors.
Therapeutic Vaccination, Immunomonitoring, Cellular Therapy
To find out more about the immunotherapies we currently have in clinical development,
go to LillyOncologyPipeline.com.
ON98796
26
04/2016
© Lilly USA, LLC 2016. All rights reserved.
27
CIMT Program
CIMT Program
Day 2 – May 11
08:00-09:30
Congress Hall
Day 2 – May 11
PLENARY SESSION 3
Chairs: Carl Figdor (Nijmegen, The Netherlands), Ugur Sahin (Mainz, Germany)
08:00-08:30
Darrell J. Irvine, MIT
"Recruiting synergistic innate and adaptive immune responses against tumors"
08:30-09:00
09:00-09:30
08:00-12:00
Watford Room
Chairs: Ralf-Holger Voss (Mainz, Germany), Isabel Poschke (Heidelberg, Germany)
10:15 -10:30
Cornelis Melief, Leiden University Medical Center
"Therapeutic vaccinaton as a component in combination treatment of cancer"
Anett Pfeiffer (#114), Paul-Ehrlich-Institute
"Towards in vivo delivery of chimeric antigen receptors"
10:30-10:45
Oliver Schoor (#120), Immatics Biotechnologies GmbH
"On- and off target toxicity profiling for adoptive cell therapy by mass spectrometrybased immunopeptidome analysis of primary human normal tissues"
10:45 -11:00
Barbara F. Schörg (# 121), Eberhard Karls University of Tübingen
"Combining tumor antigen (TA) specific Th1 cells with immune checkpoint blocking
antibodies induces tumor regression in advanced carcinomas"
11:00-11:15
Petra Simon (#124), BioNTech Cell & Gene Therapies GmbH
"Retrieval of functional TCRs from single neo-antigen-specific T cells: Toward
individualized TCR-engineered therapies"
11:15 -11:30
Parvez Vora (#125), McMaster University
"Novel immunotherapies for recurrent glioblastoma: The efficacy of CD133 BiTEs
and CAR T cells in preclinical models"
CIMT ENDEAVOUR
08:10 -09:00
Session 1: Keynote
Lothar Germeroth, Juno Therapeutics
Session 2: From Science to Products - Change of Perspectives
Chairs: Andrea Schilz (Ci3), Jutta Heix (Oslo Cancer Cluster)
CIMT-Scientist Presentations:
Nadica Mensali, Oslo University Hospital Radiumhospitalet
"Csk overexpression makes T cell dummy"
Nico Büttner, Universitätsklinikum Freiburg
"The HLA-associated phosphoproteome as a new target for immunotherapy
against hepatocellular carcinoma"
Expert Advice Panel:
Stefan Ries (Roche), Georg Schnappauf (Schnappauf & Partner), David Philipps (SR One)
10:10 -10:45
Coffee break
10:45 -11:45
Session 3: Company Stories/Successful Deals
Chair: Rainer Wessel (Ci3)
11:45 -12:00
Foyer
David Philipps, SR One
"Corporate venture investing in life sciences"
Derek Jantz, Precision BioSciences
"Precision BioSciences: a 10-year old startup"
Cedrik Britten, CIMT
Closing words
10:00-11:30
Gutenberg A
Coffee and snacks
supported by:
SHORT TALK SESSION II
New Targets, Leads and Biomarkers
Chairs: John Castle (Basel, Switzerland), Angelika Riemer (Heidelberg, Germany)
10:00-10:15
Mark Ayers (#168), Merck & Co., Inc.
"Relationship between immune gene signatures and clinical response to PD-1 blockade with
pembrolizumab in patients with advanced solid tumors"
10:15 -10:30
Michal Bassani-Sternberg (#169), University of Lausanne/CHUV
"Direct identification of neo-epitopes using in-depth immunopeptidomics of
melanoma tissues for the development of anti-tumor immunotherapies"
10:30-10:45
Marta Ilecka (#181), DKFZ Heidelberg
"Antigen-armed antibodies in the treatment of B-cell lymphoma"
10:45 -11:00
Maria Kreuzberg (#185), Ganymed Pharmaceuticals AG
"IMAB027-DM1 and IMAB027-vcMMAE, CLDN6-specific antibody-drug conjugates,
are effective against human CLDN6-positive cancer cells in vitro and in vivo"
11:00-11:15
Hideho Okada (#196), University of California San Francisco
"Novel and shared neoantigen for glioma T cell therapy derived from histone 3
variant H3.3 K27M mutation"
11:15 -11:30
Rita Pfeifer (#199), Miltenyi Biotec
"Sialyl Glycolipid Stage-Specific Embryonic Antigen 4 (SSEA4) – a novel target for
CAR T cell therapy of solid cancers"
COFFEE BREAK
28
Cellular Therapy
Gerold Schuler, Universitätsklinikum Erlangen
"Dendritic cells as cancer vaccines: taking nature´s adjuvant to a phase III trial"
Björn Philipp Kloke, CIMT
Welcome and introduction
09:00-10:10
SHORT TALK SESSION I
Bruce McCreedy (# 108), Precision BioSciences, Inc.
"Allogeneic CAR-T cells gene edited to insert an anti-CD19 CAR into the TCR alpha locus
target and kill CD19+ Raji lymphoma tumors in vitro and in vivo without causing GvHD"
08:00-08:10
09:30-10:00
Congress Hall
10:00-10:15
R&D workshop on the translation and commercialization of cancer immunotherapies
and diagnostics
10:00-11:30
29
CIMT Program
CIMT Program
Day 2 – May 11
10:00-11:30
Gutenberg B
Day 2 – May 11
SHORT TALK SESSION III
Tumor Biology & Interaction with the Immune System
Chairs: Viktor Umansky (Heidelberg, Germany), Mustafa Diken (Mainz, Germany)
14:00-15:30
Ruby Alonso (#247), Institute Curie, Inserm U932
"Infectious" tolerance transforms tumor antigen specific naive CD4 T cells into induced Tregs in a spontaneous lung tumor model"
10:15 -10:30
Marcel A. Deken (#259), Netherlands Cancer Institute
"Synergy of anti-PD-1 in combination with targeted therapy is mediated by CD8+ T cells"
10:30-10:45
Andrew Furness (#273), UCL Cancer Institute
"Characterisation of immune and tumour-specific neoantigen landscapes informs
optimal therapeutic targeting in non-small cell lung cancer"
10:45 -11:00
Remi Ramjiawan (#302), Harvard Medical School/ Massachusetts General Hospital
"c xcr4 inhibition in tumor microenvironment facilitates anti-program death
receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice"
11:00-11:15
Sunil Kumar Saini (#304), National Veterinary Institute, Technical University of Denmark
"Identification and characterization of neoepitopes associated with individual
mutational landscape in non-small cell lung cancer"
11:30 -14:00
Foyer
Els Verdegaal (#325), Leiden University Medical Center
"A changing neo-antigen landscape in human melanoma under T cell pressure"
LUNCH
13:00 -14:00
Congress Hall
Chairs: Michael Kalos (New York, USA), Cornelis Melief (Leiden, The Netherlands)
14:00-14:30
Carl June, University of Pennsylvania
"Adoptive T-cell therapy for cancer"
14:30 -15:00
Chiara Bonini, Fondazione San Raffaele del Monte Tabor
"TCR gene editing for hematological malignancies"
15:00-15:30
Robert Hawkins, Cancer Research UK
"Adoptive T-cell therapy with tumor infiltrating lymphocytes"
15:30 -18:00
15:30 -18:00
16:00-17:30
Foyer
COFFEE BREAK
Coffee and snacks
Foyer
POSTER SESSION II
New Targets & New Leads, Tumor Biology and Interaction with the Immune
System, Improving Immunity
Gutenberg A
EU CONSORTIA SESSION
Ongoing EU-funded cancer immunotherapy consortia
Chairs: Rienk Offringa (Heidelberg, Germany), Jan van de Loo (Brussels, Belgium)
16:00-16:05
Rienk Offringa, German Cancer Research Center
"Fostering interaction and synergy between ongoing EU cancer immunotherapy
consortia"
16:05-16:25
Harpreet Singh, Immatics Biotechnologies
"GAPVAC: first results from a personalized peptide vaccination study in glioblastoma"
INDUSTRY SATELLITE II
A clinician, a scientist, a pathologist: realising the promise of cancer immunotherapy
PLENARY SESSION 4
Cellular Therapy
10:00-10:15
11:15 -11:30
Congress Hall
Chair: Kenneth Bloom (San Diego, USA)
organized by:
16:25 -16:45
Ann White, University of Southampton
"IACT: The human IgG2 format imparts potent agonistic properties to immunostimulatory antibodies"
13:00-13:05
Kenneth Bloom "Welcome and introduction"
16:45-17:05
13:05-13:15
Ignacio Duran, Virgen del Rocio University Hospital
"Cancer immunotherapy: so far, so good?"
Fred Falkenburg, Leiden University Medical Center
"T-Control: therapy of hematological malignancies using streptamer-selected cell products"
17:05 -17:10
13:15 -13:25
John Haanen, Netherlands Cancer Institute
"Modulating the tumour microenvironment: the future of cancer immunotherapy"
Jan van de Loo, European Commission
"EU cancer (immunotherapy) consortia: what we are looking for in the next round"
17:10 -17:20
13:25 -13:35
Kenneth Bloom, Human Longevity, Inc.
"Personalising cancer immunotherapy: beyond morphology"
Zlatko Trajanoski, Medical University of Innsbruck
"APERIM: Advanced bioinformatics platform for PERsonalized cancer IMunotherapy"
17:20 -17:30
13:35 -13:55
Panel discussion
Sebastian Kobold, Ludwig Maximilians University Munich
"IMMUTRAIN: training network for the immunotherapy of cancer"
13:55 -14:00
Kenneth Bloom
"Summary and close"
30
31
CIMT Program
CIMT Program
Day 2 – May 11
Day 3 – May 12
Dijon Room
18:30-19:30
CIMT MEMBERS MEETING
Foyer
20:00-24:00
08:30-10:00
General Members Assembly of the Asscociation for Cancer Immunotherapy
SOCIAL EVENT AND AWARDS CEREMONY
Drinks, food and music
CIMT POSTER AWARDS SUPPORTED BY
Congress Hall
Novel Technologies for Immune Assessment
Chairs: Sjoerd van der Burg (Leiden, The Netherlands), Vincenzo Bronte (Verona, Italy)
08:30-09:00
Timothy Tree, King's College London
"Measuring regulatory T cell phenotype and function in human health and disease"
09:00-09:30
Sine Reker Hadrup, Technical University of Denmark
"Next-generation detection of cancer-responsive T cells"
09:30-10:00
Giuliano Elia, Philochem
"A phase III trial of the intralesional application of L19IL2/L19TNF in stage IIIB/C
melanoma patients"
10:00-10:30
Foyer
10:30-11:45
f ir s t- in - class immunother apies
against cancer and we believe
individualized treatments
accessible to
Gutenberg A
SHORT TALK SESSION IV
Improving Immunity
Chairs: Kris Thielemans (Brussels, Belgium), Per thor Straten (Herlev, Denmark)
10:30-10:45
Sara Colombetti (#220), Roche Pharmaceutical Research & Early Development,
Roche Innovation Center Zurich
"PD-L1 checkpoint blockade enhances anti-tumor activity of CEA TCB, a novel T-cell
bispecific antibody for the treatment of solid tumors"
10:45 -11:00
Timothy Cripe (#221), Nationwide Children's Hospital
"Seprehvir, an oncolytic herpes viroimmunotherapeutic, enhances therapeutic efficacy
of T cell checkpoint inhibition in solid tumors by increasing T cell recruitment and
remodeling the immunosuppressive microenvironment"
11:00-11:15
Nina Eissler (#224), Karolinska Institutet
"Release of IFN-γ induced chemokines provides the key to efficient combination
immunotherapy of anti-PD-1 antibody with CSF-1R inhibitor"
11:15 -11:30
Jaap Kwekkeboom (#231), Erasmus MC
"Functionality of tumor-infiltrating T cells in hepatocellular carcinoma can be
enhanced by blocking several co-inhibitory pathways"
11:30 -11:45
David Richards (#236), Apogenix AG
"Hexavalent agonists targeting receptors of the tumor necrosis factor superfamily:
TRAIL, CD40L, CD27L and beyond"
should be broadly
every single patient.
COFFEE BREAK
Coffee and snacks
We develop
PLENARY SESSION 5
PIONEERS AT WORK
32
WWW.BIONTECH.DE
33
CIMT Program
CIMT Program
Day 3 – May 12
10:30-11:45
Gutenberg B
Day 3 – May 12
SHORT TALK SESSION V
Chairs: Sebastian Kreiter (Mainz, Germany), Ulrich Kalinke (Hanover, Germany)
11:45 -13:15
Gutenberg A
SHORT TALK SESSION VI
Immunomonitoring
Chairs: Cecile Gouttefangeas (Tübingen, Germany), Marij Welters (Leiden, The Netherlands)
10:30-10:45
Marcin Cebula (#013), Helmholtz Centre for Infection Research
"TLR9 stimulation is required for recall of functional immune memory response
against neo-antigen relapse in liver"
11:45 -12:00
Amalie Kai Bentzen (#140), Technical University of Denmark
"Next-generation detection of cancer-responsive T cells using DNA barcode-labeled
peptide-Major Histocompatibility Complex I multimers"
10:45 -11:00
Naozumi Harada (#032), Mie University Graduate School of Medicine
"A novel combination immunotherapy consisting of tumor-associated macrophagetargeted vaccine, TLR agonist, and neoantigen-specific T cell transfer cures tumor
highly resistant to immune checkpoint blockade"
12:00-12:15
Coco de Koning (#146), UMC Utrecht
"CD4+ T-cell immunomonitoring after hematopoietic cell transplantation:
identifying patients at risk for virus-predicted adverse outcomes"
11:00-11:15
Zaima Mazorra (#045), Center of Molecular Immunology Havana
"Immunological results obtained in castration-resistant prostate cancer patients
treated with an EGFR-based vaccine."
12:15 -12:30
Gabriele Niedermann (#152), University Clinics Freiburg
"Noninvasive ImmunoPET imaging of the PD-1/PD-L1 checkpoint in naïve and
irradiated tumor-bearing mice"
11:15 -11:30
Anne De Groot (#048), EpiVax, Inc.
"Improved mutanome-directed cancer immunotherapy by immunoinformatic analysis of
cancer neo-epitopes for regulatory T cell activation potential"
12:30-12:45
Paulo Rodrigues-Santos (#156), Faculdade de Medicina da Universidade de Coimbra
"Immune monitoring of natural killer cells in chronic myeloid leukemia: split anergy
status depend on tyrosine kinase inhibitor therapy"
11:30 -11:45
Zane Yang (#074), Inovio Pharmaceuticals, Inc.
"Immunotherapy with INO-3112 (HPV16 and HPV18 plasmids + IL-12 DNA) in
Human Papillomavirus (HPV) associated Head and Neck Squamous Cell Carcinoma
(HNSCCa): Interim results"
12:45 -13:00
Julien Schmidt (#157), Ludwig Center of the University of Lausanne
"Isolation and analysis of tumor-specific CD8 and CD4 T cells with high affinity,
reversible pMHC multimers"
13:00-13:15
Sine Reker Hadrup, National Veterinary Institute, Technical University of Denmark
"CIP – Immunoguiding activities"
10:30-13:00
Congress Hall
REGULATORY RESEARCH SESSION
"Adoptive cellular therapies"
Chairs: Harpreet Singh (Tübingen, Germany), Michael Kalos (New York, USA)
10:30-10:40
Ulrich Kalinke, Chairman CIMT Regulaory Research Group
Introduction
10:40-11:15
Carl June, University of Pennsylvania
"Challenges in early-stage development of adoptive cell therapies"
11:15 -11:50
Gwen Binder-Scholl, Adaptimmune
"Challenges in advanced-stage development of adoptive cell therapies"
11:50 -12:25
Matthias Renner, Paul Ehrlich Institute
"Regulation of adoptive cellular therapies in Europe"
12:25 -13:00
Panel discussion, with presenters and additional panelists
Ulrich Kalinke, Carl June, Gwen Binder-Scholl, Matthias Renner,
Cedrik Britten (Glaxo Smith Kline), Peter Bross (FDA CBER)
34
11:45 -13:00
Gutenberg B
SHORT TALK SESSION VII
Clinical Trials
Chairs: Anthony Kong (Birmingham, United Kingdom), Stephan Grabbe Mainz, Germany)
11:45 -12:00
Theresa Bunse(#010), German Cancer Research Center (DKFZ)
"Immune responses to a mutation-specific peptide vaccine targeting IDH1R132H in
patients with IDH1R132H-mutated gliomas"
12:00-12:15
Markus Löffler (#43), University of Tübingen
"Personalized multi-peptide vaccination induces immune responses associated with
long term survival in a patient with metastatic intrahepatic cholangiocarcinoma"
12:15 -12:30
Matthias Miller (#047), BioNTech AG
"IVAC® MUTANOME – a first-in-human phase I clinical trial targeting individual
mutant neoantigens for the treatment of melanoma"
12:30-12:45
Raquel Gomez-Eerland (#090), NKI-AVL
"Adoptive transfer of autologous T cells modified with a MART-1 specific TCR in
advanced stage melanoma patients"
12:45 -13:00
Tanja D. de Gruijl (#222), VU University Medical Center
"Local adjuvant treatment of clinical stage I-II melanoma with CpG-B/GM-CSF improves distant recurrence-free survival: long-term follow-up of three randomized
controlled phase II trials"
35
CIMT Program
Day 3 – May 12
Foyer
13:00 -14:30
LUNCH
Congress Hall
13:30 -14:30
MEET THE EDITORS
14:30 -16:00
Cancer Research, George Prendergast
Clinical Cancer Research, Ignacio Melero
Journal for Immunotherapy of Cancer, Cornelis Melief
Science Translational Medicine, Yevgenia Nusinovich
Congress Hall
nCounter®
PanCancer Immune Profiling Panel
Explore - Understand - Create
PLENARY SESSION 6
Antibodies
Chairs: Ignacio Melero (Pamplona, Spain), Özlem Türeci (Mainz, Germany)
14:30 -15:00
Rony Dahan, The Rockefeller University
"Requirement of FcγR pathways for the therapeutic activity of immunomodulatory
antibodies"
15:00-15:30
Paul Parren, Genmab
"The molecular mechanism of complement activation by IgG: from scientific insight
to therapeutic antibody drug design"
15:30 -16:00
Laszlo Radvanyi and Kin-Ming Lo, EMD-Serono (Merck KgaA)
"PD-1/PD-L1 and beyond: new approaches and targets to overcome tumor immune"
A Multiplexed Gene Expression Approach
To Profiling Cancer Immunology
The nCounter PanCancer Immune Profiling Panel is a novel new gene
expression panel that enables researchers to develop profiles of the
human immune response in all cancer types. In collaboration with
cancer immunologists around the globe, our new 770 gene panel
combines markers for 24 different immune cell types, 30 common
cancer antigens and genes that represent all categories of immune
response including key checkpoint blockade genes.
Explore Infiltrating Cell Types
Understand Immune Pathway Activity
Create Profiles of the Immune Response in Any Cancer Type
A uniquely simple and reliable way to measure gene expression in
Cancer. The highly multiplexed, enzyme-free*, direct digital detection
technology of the nCounter System ensures that the nCounter
PanCancer Immune Profiling Panel provides high quality data from all
sample types including FFPE and PBMCs. The system features and
easy-to-use workflow and simplified data analysis.
* Single Cell assay requires reverse transcription and amplification prior to analysis on the nCounter System.
www.nanostring.com/pancancer_immune
www.nanostring.com | info@nanostring.com | 1 888 358 6266
© 2014 NanoString® Technologies. All rights reserved. NanoString®, NanoString Technologies®,
the NanoString logo, and nCounter® are registered trademarks of NanoString Technologies, Inc.,
(“NanoString”) in the United States and/or other countries.
36
FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
CIMT Information
ANNUAL MEETING
2016
INDUSTRY
EXHIBITORS
Meet us at Verapido’s CIMT Industry Exhibition booth,
May 10-12, and at CIMT Endeavour, May 11, 8:00-12:00
See our Abstract Number P219 and our poster at the ‘Improving
Immunity’ Poster Session, May 11, 15:30-18:00
A Novel,
Convenient Intradermal
Injection Device
Vaccines, Immunotherapies
for Intracutaneous
Peptides, Proteins, Antibodies
Injections
Insulin and other Hormones
Nucleic Acids
Hahn-Schickard
Verapido Medical GmbH
Wilhelm-Schickard-Straße 10
D-78052 Villingen-Schwenningen
Baden-Württemberg, Germany
www.Hahn-Schickard.de
Contact
Dr. med. Markus Clemenz
Telephone: +49 7721 943-141
E-mail:
Markus.Clemenz@Verapido.com
Markus.Clemenz@Hahn-Schickard.de
www.Verapido.com
39
CIMT Information
CIMT Information
[ A ] Acris Antibodies - . . . . . . . . . . . B006
OriGene EV
Schillerstraße 5
32052 Herford, Germany
www.acris-antibodies.com
Antikörper, Proteine, C DNA Klone
ANNUAL MEETING
2016
INDUSTRY
EXHIBITORS
Adaptive Biotechnologies . . . . . . B002
1511 Eastlake Ave E, Suite 200
Seattle, Washington 98102, USA
Advanced Cell Diagnostics . . . . . B015
Via Calabria 15
20090 Segrate, Italy
www.acdbio.com
RNAscope
AID GmbH. . . . . . . . . . . . . . . . . A016
Ebinger Straße 4
72479 Strassberg, Germany
www.aid-diagnostika.com
Imerge Analyzer
Rheinufer
B017
B016
B011
B012
B018
B014
B013
B020
B019
B015
Main Entrance
Rhine Foyer
B008
B007
Watford- and
Dijon-Room
B004
B006
B003
Astra Zeneca GmbH. . . . . . . . . . B012
Tinsdaler Weg 183
22880 Wedel, Germany
www.astazeneca.de
www.azimmuno-oncology.com
Combinations in Immuno-Oncology
Participants
Registration
Wardrobe
B005
B010
AmpTec GmbH . . . . . . . . . . . . . B013
Königstraße 4 A
22762 Hamburg, Germany
www.amp-tec.com
Synthetische mRNA
[ B ] Beckman Coulter GmbH . . . . . . A016
Europark Fichtenhain
47807 Krefeld, Germany
www.beckman.com
Flow Cytometry
B001
A022
A021
A002
A020
A019
A003
City Hall Platform
Jockel-Fuchs-Platz
Underground Car Park
A007
Catering
A006
North Foyer
Congress Hall
A005
Gutenberg A and B
A008
A009
A016
A011
A015
A012
C001
A013
Becton Dickinson GmbH. . . . . . B005
Tullastraße 8-12
69126 Heidelberg, Germany
www.bdbiosciences.com/us/home
BioLegend . . . . . . . . . . . . . . . . . B020
9727 Pacific Heights Blvd.
San Diego, CA 92121, USA
www.biolegend.com
BIO-SYS GmbH. . . . . . . . . . . . . . A005
Kiefernweg 10
61184 Karben, Germany
www.biosys.de
Bioreader®
A017
A010
South Foyer
A018
A004
West Foyer
14
A0
Biozol. . . . . . . . . . . . . . . . . . . . . B019
Diagnostica Vertrieb GmbH
Obere Hauptstraße 10b
85386 Eching, Germany
www.biozol.de
MHC Tetramere/Monomere,
Antikörper, ELISA, Proteine
[ C ] Rheinstraße
40
Charles River Research . . . . . . . . B007
Models and Services
Sandhofer Weg 7
97633 Sulzfeld, Germany
www.criver.com
Alzet Osmotische Pumpen, Research
Models, Jax Mice Models
CI3 Management UG . . . . . . . . . A014
Hölderlinstraße 8
55131 Mainz, Germany
www.ci-3.de
CTL Europe GmbH. . . . . . . . . . . A022
Hans-Boeckler-Straße 19-29
53225 Bonn, Germany
www.immunospot.eu
ELISPOT ANALYZERS, KITS, SERUMFREE MEDIA,
CRYOPRESERVED PBMC
[ E ] eBioscience, an . . . . . . . . . . . . . A004
Affymetrix company
Campus Vienna Biocenter 2
1030 Vienna, Austria
www.ebioscience.com
Forschungsreagenzien
[ J ] [ P ] JPT Peptide Technologies . . . . . . B008
Volmerstraße 5
12489 Berlin, Germany
www.jpt.com
Peptide
PANTEC Biosolutions AG. . . . . . A009
Industriering 21
9491 Ruggell, Liechtenstein
www.pantec-biosolutions.com
P.L.E.A.S.E. Professional Lasergerät
[ L ] Lilly Oncology. . . . . . . . . . . . . . B010
Lilly Corporate Center, Indianapolis
IN 46285, USA
www.lillyoncology.com
Lophius Biosciences GmbH . . . . . B001
Josef-Engert-Straße 13
93053 Regensburg, Germany
www.lophius.com
Produkte und Serviceleistungen für
die immunologische Forschung und
Diagnostik
[ M ] PEPperPRINT. . . . . . . . . . . . . . . A017
Rischerstraße 12
www.pepperprint.com
Peptide Microarrays, Epitope Mapping,
Serum Signature Analysis
Personalis Inc.. . . . . . . . . . . . . . A012
7330 O'Brien Drive
CA 94025 Menlo Park, USA
www.personalis.com
NGS-Services for Immuno-Oncology
and Cancer Dx
PeproTech GmbH. . . . . . . . . . . . A015
Oberaltenallee 8
www.peprotech.com
Proteine, Antikörper, ELISA, …, Medien
Mabtech AB. . . . . . . . . . . . . . . . B004
Augustendalsvägen 19
13152 Nacka Strand, Sweden
www.mabtech.com
ELISpot, ELISA, Antibodies
PromoCell GmbH. . . . . . . . . . . . A018
Sickingenstraße 63/65
www.promocell.com
Meso Scale Discovery.. . . . . . . . C001
1601 Research Blvd
20850, Rockville, USA
www.mesoscale.com
U-PLEX, S-PLEX, V-PLEX
Proteintech Europe Limited. . . . A002
Manchester Science Park, Kilburn House
Manchester M15 6SE, United Kingdom
www.ptglab.com
Autibodies + ELISA Kits
B002
East Foyer
A001
CENIBRA GmbH . . . . . . . . . . . . A011
Große Straße 17
49565 Bramsche, Germany
www.cenibra.de
Cellometer Cell Counter, Celigo
Imaging Cellometer, CQ1 High
Content Analyser
CellGenix GmbH . . . . . . . . . . . . B017
Am Flughafen 16
79108 Freiburg, Germany
www.cellgenix.com
Cytokines, Media,Supplements+ alls
Essen Bioscience. . . . . . . . . . . . B014
BioPark, Broadwater Road
AL73AX, Welwyn Garden City, United
Kingdom
www.essenbioscience.com
Miltenyi Biotec GmbH. . . . . . . . B011
Friedrich-Ebert-Straße 68
51429 Bergisch Gladbach, Germany
www.miltenyibiotec.com
EUFETS GmbH. . . . . . . . . . . . . . A020
Vollmersbachstraße 66
55743 Idar-Oberstein, Germany
www.eufets.com
[ N ] [ G ] GE Healthcare Europe. . . . . . . . A019
GmbH
Munzinger Straße 5
79111 Freiburg, Germany
www.gelifesciences.com
Xuri
[ I ] IBA GmbH . . . . . . . . . . . . . . . . . A003
Rudolf-Wissell-Straße 28
37079 Göttingen, Germany
www.iba-lifesciences.com
www.fabian-online.com
FaBian®, CELLina®
Immudex. . . . . . . . . . . . . . . . . . A001
Fruebjergvej 1
DK-2100 Copenhagen, Denmark
www.immudex.com
Dextramers
NanoString Technologies. . . . . . B003
Germany GmbH
Alsterwiete 3
www.nanostring.com
Nano String Technologies nCounter
Analysis System and NanoString Technologies Codesets
New England Biolabs. . . . . . . . . A006
Cell Signaling Technology
Brüningstraße 50, Gebäude B 852
69926 Frankfurt am Main, Germany
www.neb-online.de
Reagenzien für die Krebsforschung,
Zell- und Molekularbiologie
[ O ] OLS, OMNI Life Science. . . . . . . A010
GmbH & Co KG
Karl-Ferdinand-Braun-Straße 2
28359 Bremen, Germany
www.ols-bio.de
xCELLigence, NovoCyte, CASY
[ S ] Sino Biological Inc. . . . . . . . . . . A013
Suite B-210-C, 14 Zhong He Street, BDA
Beijing 100176, China
www.sinobiological.com
Proteins, Antibodies, cDNA Clones, Elisa
Kits, Resins, and other Research Tools
[ T ] ThermoFisher Scientific . . . . . . A007
Frankfurter Straße 129B
64293 Darmstadt, Germany
www.thermofisher.com
Flow Cytometry
The Jackson Laboratory . . . . . . B018
600 Main Street
04609 Bar Habor, Maine, USA
www.jax.org
TRON - . . . . . . . . . . . . . . . . . . . A021
Translationale Onkologie an
der Universitätsmedizin der Joh.
Gutenberg Universität Mainz
Freiligrathstraße 12
www.tron-mainz.de
[ V ] Verapido Medical GmbH . . . . . . A008
Wilhelm-Schickard-Str. 10
78052 Villingen-Schwenningen, Germany
www.verapido.com
Dermaject Intradermales Injektionsgerät
41
CIMT Information
POSTER AWARD
POSTER
PRESENTATIONS
Abstracts have been selected for poster
presentation in six categories.
Cellular Therapy
Immunomonitoring
Poster Session I, May 10, 15:00-17:30, Foyer
New Targets & New Leads
Poster Session II, May 11, 15:30-18:00, Foyer
Improving Immunity
2016 CIMT
Poster Award
SPONSORED BY
Tumor Biology & Interaction
with the Immune System
42
CIMT Abstracts
FZI
Research
Center for
Immunotherapy
Abstract List (001 - 019)
No.:
Presenter: WHAT IS THE FZI?
001
Variation
Allagui-
The Research Center for Immunotherapy (FZI) is one of the major focus areas
of biomedical research within the Johannes Gutenberg University in Mainz. It is
located mostly on the medical campus and is composed of almost 50 research
groups. With a dedicated research building, several core facilities, regular lecture
series and a structured graduate and postgraduate training program, the vision of
the FZI is to be one of Germany‘s prime locations for immunology research.
002
Angerer-
Blood
003
Aurisicchio-Epitope-minigenes
004
Baert-
Dendritic
005
Banki-
Combination
006
Bialkowski-Intralymphatic
007
Bigalke-
WT-1
008
009
Bulgarelli-
The
010
Bunseyes
Immune
011
Buonaguro-Discovery
012
Capasso-
An
013
Cebulayes
TLR9
014
Conner-
Immune
015
016
Dal Col-
Coding-
017
de Haar-
Development
018
Deiser-
Next-generation
019
Dewitte-
Theranostic
NEW AT THE FZI:
The FZI represents outstanding third party projects on the way to an excellence
center of immunological research in Germany:
•  TR SFB 156 „The skin as sensor and effector organ, orchestrating local and
systemic immunity“ – together with Heidelberg and Tübingen
•  SPP 1937: „Innate Lymphoid Cells“ – coordinated by Prof. Dr. A. Diefenbach
EVENTS CO-ORGANIZED BY
THE FZI:
FZI-SEMINAR SERIES
01. - 03.06.2016:
10th German Meeting on
Immune Regulation, BerlinSchmöckwitz, Germany
27. - 28.06.2016:
19th T-Cell Meeting- Subsets
and Functions, Marburg,
Germany
04. - 07.07.2016:
1st Frankfurt Conference on
Ubiquitin and Autophagy,
Frankfurt/Main, Germany
20.11. – 02.12.2016:
EMBO conference “Innate
lymphoid cells – 2016”, Berlin,
Germany
02.06.2016, 17.15: Wolfgang Weninger
16.06.2016, 17:15: Daniel Saban
07.07.2016, 17:15: Jonathan Kipnis
08.09.2016, 17:15: Hans-Reimer Rodewald
17.11.2016, 17:30: Mihai Netea
15.12.2016, 17:30: Bernard Malissen
(UMC Mainz, building 706, lecture hall):
UNIVERSITY MEDICAL CENTER of the Johannes Gutenberg University Mainz, Research Centre for Immunotherapy
(FZI), Obere Zahlbacherstr. 67 , Building 905, D-55131 Mainz, Phone: +49 6131 178114 www.fzi.uni-mainz.de
Shor t talk:
Title:
in susceptibility for human malignant melanomas to oncolytic measles virus
DC preparations generated using automated CliniMACS Prodigy CD1c/CD304
enrichment and activation System efficiently activate CD8+ antigen-specific T-cells
for optimal induction of the immune response against tumor
associated antigens
cell immunotherapy in ovarian cancer: an immunosuppressive challenge
of oncolytic virotherapy and DC-based immunotherapy for the treatment of melanoma
mRNA vaccine induces CD8 T-cell responses that inhibit the growth
of mucosally located tumors
and PRAME mRNA transfected TLR 7/8 polarized fast DCs can raise specific
immune responses in AML patients that correlate with clinical outcome
-
This abstract has been withdrawn
double face of dendritic cell vaccination in metastatic melanoma: inducing
intratumor immune response can switch tumor cells toward dedifferentiated state
responses to a mutation-specific peptide vaccine targeting IDH1R132H in
patients with IDH1R132H-mutated gliomas
to first-in-man studies of a multi-peptide-based hepatocellular carcinoma
vaccine adjuvanted with CV8102 (RNAdjuvant®) - HEPAVAC
Epitope Discovery and Improvement System (EDIS) to study MHC-I epitopes and
improve their sequences
stimulation is required for recall of functional immune memory response
against neo-antigen relapse in liver
responses following intrapleural administration of the oncolytic HSV Seprehvir in patients with malignant pleural mesothelioma
-
and non coding-RNA profiling of active dendritic cells following stimulation with highly immunogenic tumor cell lysates
of a GMP production protocol for a cord blood-derived dendritic
cell-based vaccine to prevent relapses after hematopoietic cell transplantation in
children with AML
dendritic cell vaccination in postremission therapy of AML: results
of a clinical phase I trial
mRNA-loaded microbubbles for ultrasound-assisted dendritic cell
based cancer vaccination
45
CIMT Abstracts
CIMT Abstracts
No.:
Presenter: 020
MERIT:
Dorer-
021
Dörrie-
A phase
022
023
Shor t talk:
Title:
No.:
Presenter: Individualized cancer vaccines for the treatment of TNBC – a phase I trial
039
Design
Kramer-
I/II clinical trial on malignant melanoma with in vitro optimized mRNAelectroporated dendritic cells as therapeutic vaccine
040
Kuttruff-Coqui-
041
Kyzirakos-
A
042
Lichty-
Oncolytic
043
Löffleryes
Personalized
Eyrich-
Dendritic
cell vaccination with partial Treg depletion in relapsed glioblastoma –
results from the pilot phase of the HIT-HGG Rez Immunvac study
Eyrich-
Characterization
of TLR3/8-PGE2 versus TNFα/IL-1ß matured dendritic cells produced for clinical vaccination trials: impact of maturation on migration and T-cell
priming/crosspresentation capacities
Title:
of reversible antigen-adjuvant conjugates for triggered release inside
antigen-presenting cells
GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide
vaccination trial in patients with newly diagnosed glioblastoma
pipeline for fast track identification of candidate neoantigens from cancer exome
sequencing data
viral immunotherapy of HPV+ cancer
multi-peptide vaccination induces immune responses associated with
long term survival in a patient with metastatic intrahepatic cholangiocarcinoma
024
Feger-
ORFV
025
Fotaki-
Allogeneic
044
Lybaert-
Innovative
026
Frøsig-
The
Ellegaard Göttingen minipig as a large animal model for anti-cancer vaccination
045
Mazorrayes
Immunological
027
Gaudernack-
UV1 – a second-generation, peptide-based, therapeutic cancer vaccine targeting the
reverse transcriptase subunit of human telomerase (hTERT)
046
Mikyšková-Cancer
047
Milleryes
IVAC®
048
Moiseyes
Improved
049
Montico-
Exploiting
050
Mottas-
Mixed
051
Müller-
The
052
Nair-
Oncolytic
053
Nelde-
Identification
054
Orlinger-
Development
028
Vector Vaccines – therapeutic potency in robust CRPV rabbit tumor model
Shor t talk:
dendritic cells (AlloDCs) transduced with an infection-enhanced adenovirus as adjuvant for cancer immunotherapy
Gerer-
Immunotherapy
of the Merkel Cell Carcinoma by vaccination with optimized DCs
transfected with the viral oncogenic driver – the large T antigen
029
Grees-
Development
030
Grenov-
Developing
of dendritic cell vaccination for combined melanoma immunotherapy
a cancer vaccine for two-dimensional T cell activation using the Invari-
ant chain
Flt3L-based in situ vaccination for the treatment of lymphoma
031
Hammerich-
032
Haradayes
A novel
033
034
035
combination immunotherapy consisting of tumor-associated macrophagetargeted vaccine, TLR agonist, and neoantigen-specific T cell transfer cures tumor
highly resistant to immune checkpoint blockade
Heidenreich-
RNAdjuvant®, a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile
Høgset-
Photochemical
internalization – light-induced enhancement of MHC Class I antigen
presentation, giving strong enhancement of cytotoxic T-cell responses to vaccination
Holmberg-Peptide
vaccination against cancer testis antigens in combination with hypomethylating treatment for patients with Myelodysplastic Syndrome and Acute Myeloid
Leukemia: An ongoing phase I study
results obtained in castration-resistant prostate cancer patients
treated with an EGFR-based vaccine.
immunotherapy using dendritic cells pulsed with tumor cells killed by high
hydrostatic pressure in murine models for prostate cancer
MUTANOME – a first-in-human phase I clinical trial targeting individual
mutant neoantigens for the treatment of melanoma
mutanome-directed cancer immunotherapy by immunoinformatic analysis of cancer neo-epitopes for regulatory T cell activation potential
immunogenic cell death features for improved dendritic cell-based therapeutic vaccine against mantle cell lymphoma
ligand coated gold nanoparticles as carrier of R848 for cancer immunotherapy
mechanism of immune stimulation by Orf virus – a novel viral vector for
therapeutic cancer vaccines
poliovirus activates antigen-presenting cells and promotes anti-cancer
responses in vitro and in vivo
and characterization of HLA class I-restricted MYD88 L265P-derived
peptides as tumor-specific targets for immunotherapy
of novel replication-defective lymphocytic choriomeningitis virus vectors expressing HPV-16 antigens for immunotherapy
036
Hooijberg-
Extent
055
Peres-
Polymeric
037
Hoyer-
BRAF
056
Podola-
A phase
038
Jabulowsky- A
057
Podrazil-
Immunological
46
and location of tumor infiltrating lymphocytes in microsatellite stable colon
cancer predict outcome to adjuvant Active Specific Immunotherapy
generic strategies for the encapsulation of patient-specific cancer antigens into immune-modulating particles
and MEK inhibitors influence human immune cell phenotype and function
first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles for potent cancer immunotherapy in patients
nanoparticle-based vaccine to target dendritic cells and the tumor microenvironment
2a trial and related preclinical studies to investigate the immunologic
impact, anti-tumor efficacy and safety of VXM01, an oral T-cell inducing vaccine,
in late stage colorectal cancer patients
parameters in phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) in patients with rising PSA after primary prostatectomy or
salvage radiotherapy for prostate cancer
47
CIMT Abstracts
CIMT Abstracts
Cellular Therapy
No.:
Presenter: Shor t talk:
Title:
058
iVacALL:
Rabsteyn-
A personalized peptide-vaccination design platform for pediatric acute
lymphoblastic leukemia patients based on patient-individual tumor-specific variants
059
Rabu-
Optimizing
synthetic long peptide-based anti-tumor vaccination using protease
sensitive linkers
060
Ramachandran-
Preclinical evaluation of triple microRNA-attenuated oncolytic Semliki forest virus
in glioma and neuroblastoma
061
Rammensee-
A new synthetic lipopeptide is a superior adjuvant for peptide vaccination
062
063
Rothe-
Enhancing
064
Sainz-
Promising
-
dendritic cell-induced T-cell responses by immunomodulating agents
melanoma therapeutic cancer vaccine based on hybrid lipid-polymeric
nanoparticles
065
Sanders-
Xenogeneic
066
Schütz-
Immunomodulatory
068
Shor t talk:
075
Identifying
Allard-
076
Amann-
Targeting
capacity of CD47 functionalized artificial antigen-presenting
combination of vasculature disrupting agent with TLR7/8 agonist:
Promising strategy for melanoma therapy
pseudotyped oncolytic vesicular stomatitis virus for the treatment of
prostate cancer
077
Audehm-
Comparison
078
Berger-
Generation
079
Bianchi-
Development
080
Bonte-
Functional
081
Brey-
Targeting
082
Campillo-Davo-
RNAi-mediated silencing of endogenous TCR enhances tumor killing activity of
TCR-engineered WT1 peptide-specific CD8+ T cells
083
Cappuzzello-
Enhancing Cytokine-Induced Killer cell activity with Her2-specific Fc-engineered
antibodies and antibody derivatives
084
Chaperot-
Potential
070
Van der Jeught-
innate immune effector cell recruitment by interleukin-15 dendritic cells
085
Cripe-
Seprehvir,
Type I IFN induced upon particle mediated intravenous delivery of antigen mRNA
enhances specific immune responses
086
Dutoit-
MET-specific
CARs for cell therapy of patients with GBM
071
Verbeke-
Messenger
RNA DOTAP-Cholesterol lipoplexes containing TLR agonists allow single step antigen-loading and maturation of dendritic cells
087
Fåne-
Development
of novel chimeric antigen receptors (CAR) to treat B-cell malignancies
072
Vormehr-
Neo-epitopes
073
Wollmann-LCMV-GP
074
Yangyes
Immunotherapy
generated by insertions, deletions and gene fusions as targets for
personalized tumor vaccination
088
Friese-
Constructing
pseudotyped oncolytic vesicular stomatitis virus for the treatment of
ovarian cancer
089
Gary-
Insights
with INO-3112 (HPV16 and HPV18 plasmids + IL-12 DNA) in Human Papillomavirus (HPV) associated Head and Neck Squamous Cell Carcinoma
(HNSCCa): Interim results
090
Gomez-Eerlandyes
091
Hillerdal-
Characterization
092
Hodgins-
Liposomes
093
Inderberg-
Adoptive
rare, high avidity self/tumor-specific CD8 T cells in cancer patients
of two allorestricted T-cell receptors targeting two different Myeloperoxidase-derived HLA-B*07:02-restricted peptide epitopes with different MHC affinities with respect for their therapeutic potential
of chimeric antigen receptor - modified memory stem cell CD8+ T
lymphocytes from naive precursors by modulation of Wnt/ß-catenin pathway or
inhibition of Akt-signaling
of imaging strategies for investigation of TCR with defined antitumor
reactivity in vivo
evaluation of tumor antigen specific T-cells generated from TCR transduced human hematopoietic stem cells
Urbiola-
LCMV-GP
Van Acker-Superior
Title:
simultaneously non-mutated HLA.A2-restricted MDM2 and p53 tumorassociated antigens as a novel double-edged swords approach for TCR gene therapy
for multiple myeloma
Seth-
Synergistic
069
48
Presenter: vascular endothelial growth factor-2 vaccination in tumor bearing mice
cells (aAPCCD47+)
067
No.:
HCMV-infected fibroblasts with bi-specific CAR-T cells
immunogenicity of PUVA-induced cell death
an oncolytic herpes immunotherapeutic, enhances GD2-directed Chimeric
Antigen Receptor (CAR) T-cell therapy in GD2-expressing solid tumor xenografts
artificial antigen-presenting cells for improved T-cell function in
adoptive T-cell therapy of melanoma
into the preventive/preemptive adoptive transfer of CMV- and EBV-specific
peptide-stimulated T cells after allogeneic stem cell transplantation as part of the
phase I/IIa clinical trial MULTIVIR-01
Adoptive transfer of autologous T cells modified with a MART-1 specific TCR in
advanced stage melanoma patients
of the avidity of TCR-engineered T cells with novel and established approaches
encapsulating zoledronic acid for cancer immunotherapy and their effect on the in vivo biodistribution of Vg9/Vd2 T cells in different tumour models
immunotherapy with a little help from CD4 T cells
49
CIMT Abstracts
CIMT Abstracts
Cellular Therapy
Cellular Therapy
No.:
Presenter: vitro stimulation conditions affect the immune phenotype of both CD4+ and
CD8+ T cells expressing a GD2-specific chimeric antigen receptor
113
Exploiting
Owens-
recovery of innate immune cells after αβ T-cell depleted allogeneic stem cell
transplantation from matched related and unrelated donors
114
Pfeifferyes
Towards
115
Raemdonck-
Exploring novel siRNA delivery approaches with cytotoxic T cells
116
Kayser-
CD4+
117
Rataj-
Arming
098
Kirkin-
Development
118
Sandri-
Feasibility
099
Klaver-
Plasma
119
Schaft-
Receptor-transfected
120
Schooryes
On-
No.:
Title:
094
In
Jamitzky-
095
Janssen-
Rapid
096
Jin-
Safe engineering
097
of CAR T cells for adoptive cell therapy of cancer using long-term
episomal gene transfer
T-helper-1 cells against the tumor antigens WT1, NY-ESO-1, ROR1, MAGE-A3
and Survivin for adoptive transfer to treat cancer
of multi-groove tissue culture flasks for growing of lymphocytes used
in adoptive immunotherapy
IFNγ and IL-6 levels correlate with peripheral T-cell numbers in RCC patients treated with CAR T-cells
Shor t talk:
Title:
tumour infiltrating lymphocytes (TILs) as a therapeutic strategy in ovarian cancer – a proof of concept study
-
in vivo delivery of chimeric antigen receptors
T cells with activating FcγRIIIa receptors for antibody redirected lysis of
cancer cells
of telomerase-specific adoptive T-cell therapy for hematologic and solid
malignancies
and off target toxicity profiling for adoptive cell therapy by mass spectrometrybased immunopeptidome analysis of primary human normal tissues
100
Kraus-
Functional
101
Kremer-
CXCR2
121
Schörgyes
Combining
102
Kunert-
TCRs
122
Schütt-
Two
123
Schütz-
Nanoparticle
103
Kunert-
Intra-tumoral
124
Simonyes
Retrieval
104
Lameris-
Activation
125
Singhyes
Novel
105
Legscha-
Targeting
126
Solum-
Serum
106
MacLeod-
Integration
127
107
Mall-
Mapping
128
Such-
Characterization
108
McCreedyyesAllogeneic
129
Taborska-
Human
109
Mensali-
Csk
130
Tosi-
Identification
110
Mroz-
Individualized
131
Tubb-
Targeting
132
Uslu-
Generating
for MAGE-C2, in combination with epigenetic drug treatment of target cells,
yield tumor-selective therapeutic T cells
production of IL18, but not IL12, by ‘smart’ T cells is non-toxic and
counteracts immune evasion of solid tumors, prolonging survival
of invariant natural killer T-cells by a unique anti-CD1d single domain
antibody induces potent tumor destruction in vitro
tumor suppressor p53 isoforms as a novel approach to improve T-cell
based immunotherapy
of a CD19 CAR gene into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells
of T-cell receptor-engineered human T cells at the tumor site by Immuno-PET
CAR-T cells gene edited to insert an anti-CD19 CAR into the TCR alpha
locus target and kill CD19+ Raji lymphoma tumors in vitro and in vivo without
causing GvHD
overexpression makes T cell dummy
immunotherapy of ovarian cancer by targeting Claudin-6 with CARengineered T cells
111
Oberoi-
Generation
112
50
characterization of different variants of a PD-1-CD28-fusion receptor
chemokine receptor transduction of human NK cells to improve migration
to solid tumors
of tumor-specific NK cells by differentiation of CAR-gene transduced
hematopoietic progenitors
-
γ/δ T cells; the new magic bullets against melanoma?
tumor antigen (TA) specific Th1 cells with immune checkpoint blocking antibodies induces tumor regression in advanced carcinomas
are better than one?! Improving safety for CAR T cell therapy
based antigen-specific redirection of T cells to tumors
of functional TCRs from single neo-antigen-specific T cells: Toward individualized TCR-engineered therapies
immunotherapies for recurrent glioblastoma: The efficacy of CD133 BiTEs
and CAR T cells in preclinical models
replacement might substitute human serum in the GMP production of Dendritic Cells
-
of recognition profiles of TCRs by a novel DNA-barcode based
multiplex technology
dendritic cells pulsed with high hydrostatic pressure-inactivated prostate
cancer cells and matured with poly(I:C) induce autologous lymphocytes to ex vivo
recognize and kill prostate cancer cells
of a HLA-A*0201-restricted immunogenic epitope from the universal
tumor antigen DEPDC1
of recurrent somatic cancer mutations for T cell receptor gene therapy
T cells expressing two additional receptors (TETARs) by combining a
chimeric antigen receptor and a conventional T-cell receptor for multi-hit cancer
immunotherapy
51
CIMT Abstracts
CIMT Abstracts
Cellular Therapy
Immunomonitoring
No.:
Title:
133
A novel
Voss-
134
Wälchli-
A universal
135
Weinstein-Marom-
stabilized single chain TCR format allows for the generation of virus/tumor
antigen-bispecific human T-cells and prevents mispairing with endogenous TCRs
killer T-cell for adoptive cell therapy of cancer
Enhancing the effector functions of T cells with a combination of new mRNA adjuvants for improving adoptive cell therapy
136
Wennhold-Tumorantigen-Specific
137
Westergaard-
138
No.:
139
Massive
Andersen-
140
Bentzenyes
Next-generation
141
Challis-
CIP
142
Chandran-
Automated
143
Chiang-
Radiation-expanded
144
Coosemans-
145
de Goeje-
Immune
146
de KoningyesCD4+
147
Galaine-
Immunoprevalence
148
Gouttefangeas-
149
Krebs-
Evaluation
multiplexing: DNA barcode Dextramers for T cell epitope discovery and
epitope profiling
detection of cancer-responsive T cells using DNA barcode-labeled
peptide-Major Histocompatibility Complex I multimers
NK proficiency panel 2016: Reducing inter-lab variation in NK activation and
functional markers, CIP
CD40-activated B cells for cancer immunotherapy
Preclinical development of Tumor-Infiltrating Lymphocytes (TILs) based Adoptive
Cell Transfer Immunotherapy (ACT) for patients with advanced ovarian cancer
NK cells display potent activity against glioblastoma and induce protective antitumor immunity
Title:
flow cytometry analysis by ReFlow
myeloid-derived suppressor cells are responsible for local failure of radiation therapy
Zhang-
Targeted
Preliminary results of a prospective immunomonitoring trial in ovarian cancer
patients
monitoring of lung cancer patients to predict clinical outcome using an
automated pipeline for flow cytometry data analysis
T-cell immunomonitoring after hematopoietic cell transplantation: identifying patients at risk for virus-predicted adverse outcomes
and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4 Th1 responses against telomerase in cancer patients
Immunomonitoring and immunoguiding: update on the CIP activities, CIP
of novel predictive marker molecules in malignant melanoma immuno-
therapy
150
Lyngaa-
Type,
frequency and breadth of tumor associated antigen reactivity in tumor infiltrating lymphocyte from metastatic melanoma patients
151
Mandruzzato-
Results from the first phase of a harmonization effort for the phenotyping of human myeloid-derived suppressor cells, CIP
152
Niedermannyes
Noninvasive ImmunoPET imaging of the PD-1/PD-L1 checkpoint in naïve and irradiated tumor-bearing mice
153
Omokoko-
NGS-based
154
Peper-
Peptide-specific
αβTCR repertoire analysis in tumor and blood from three melanoma
patients pre and post IVAC® MUTANOME vaccination
T-cell responses against tumor-specific HLA ligands in ovarian
cancer
52
155
Rathinasamy-
Tumor antigen specific Treg from the bone marrow migrate towards increased S1P
and CCL2 gradients established in the blood of breast cancer patients
156
Rodrigues-Santosyes
Immune monitoring of natural killer cells in chronic myeloid leukemia: split anergy
status depend on tyrosine kinase inhibitor therapy
157
Schmidtyes
Isolation
and analysis of tumor-specific CD8 and CD4 T cells with high affinity,
reversible pMHC multimers
53
CIMT Abstracts
CIMT Abstracts
Immunomonitoring
No.:
Presenter: 158
PD-1
Simon-
159
Stam-
Systemic
160
Shor t talk:
Title:
blockade induces quantitative and qualitative changes within a vast and common antigen-specific T cell repertoire in melanoma treated patients
WT-1 specific T cell reactivity in relation to immune status and survival
following ablative treatment of locally advanced pancreatic cancer by irreversible
electroporation
Tudor-
An optimized
IFN-γ ELISpot assay to determine CMV protein-reactive effector cells
of cell- mediated immunity
161
Turksma-
Antigen-specific
T cell immunomonitoring by HLA tetramer combinatorial coding
for CD8 T cells and CD40L expression on antigen-specific CD4 T cells
162
Vigano-
Clinical
163
Welters-
Detection
164
Welters-
A kit
165
Wistuba-Hamprecht-
Associations of peripheral blood Vδ1+ γδ T-cells with overall survival of melanoma
patients
166
Zelle-Rieser-
Bone marrow T cells from myeloma patients exhibit features of both T-cell exhaustion and senescence
immunomonitoring strategies assessing on-target and off-target effects of
anti-CD73 mAbs - The TumAdoR collaborative project
and functional assessment of regulatory T cells in clinical samples, CIP
for the preparation of T-cell Receptor Engineered Reference Sample (TERS) to
control T-cell assay performance, CIP
No.:
Title:
167
Identifying
Ashfield-
168
Ayersyes
Relationship
169
Bassani-Sternbergyes
170
Beck-
Validation
tumour-specific Class I MHC peptide epitopes by Mass Spectrometry
between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab in patients with advanced solid tumors
Direct identification of neo-epitopes using in-depth immunopeptidomics of melanoma tissues for the development of anti-tumor immunotherapies
of a clinical 1400-gene assay for genomic profiling of cancer from DNA
and RNA
cancer therapies – a role for cold physical plasma against pancreatic
malignancies in vitro and in vivo
171
Bekeschus-ROS-based
172
Braitbard-
Signal
173
Bräunlein
174
Buettner-
The
175
Charpentier-
Within the family of MELOE antigens, IRES-dependent translation conditions exclusive expression in melanoma cells and immunogenicity
176
Deumelandt-
Ex vivo expansion of human glioma-infiltrating lymphocytes alters the exhaustion
phenotype of T cells
177
Di Marco-
A
178
Doorduijn-
A
179
Doorduijn-
TAP-independent
peptide derived monoclonal antibodies impair mmtv-associated tumor
growth
-
Immunogenicity assessment of mutated HLA-ligands identified on melanoma tissue
probes by mass spectrometry
HLA-associated phosphoproteome as a new target for immunotherapy against
hepatocellular carcinoma
“multi-omics approach” for the identification of T cell epitopes in clear cell renal
cell carcinoma
novel role for CD4+ T cells in clearance of highly aggressive MHC-I low tumors
mediated via NK cells
self-peptides enhance T cell recognition of immune-escaped
tumors
54
Genetic engineering using CRISPR/Cas9: Targeting MMP23 in melanoma
180
Halldórsdóttir-
181
Ileckayes
Antigen-armed
182
Kedde-
A novel
183
Krächan-
A novel
184
-
185
KreuzbergyesIMAB027-DM1
186
Kwekkeboom-
antibodies in the treatment of B-cell lymphoma
highly tumor-specific antibody for acute myeloid leukemia and myelodysplastic syndrome targeting a sialylated epitope of CD43
TLR7 agonist reverses NK cell anergy and cures lymphoma-bearing mice
and IMAB027-vcMMAE, CLDN6-specific antibody-drug conjugates,
are effective against human CLDN6-positive cancer cells in vitro and in vivo
Tumor expression of immune inhibitory molecules and TIL counts predict pancreatic cancer survival
55
CIMT Abstracts
CIMT Abstracts
No.:
Title:
187
Targeting
Lee-
188
Leon-
Human
189
Leon-
Blocking
190
Marillier-
PF-06840003:
191
192
of reactive oxygen species can be a potential therapeutic strategy for
cancer treatment
IL-2 agonist exhibits a higher antitumor efficacy and lower toxicity than
wild type IL-2 in different preclinical contexts
IL-2 signal in vivo with IL-2 antagonist reduces tumour growth through
the control of regulatory T cell accumulation
No.:
Title:
206
The
Schuster-
207
Schwenck-Clinical
208
Shuttleworth-
KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110β/
p110δ and HDAC6 with single-agent and combination activity
immunopeptidomic landscape of ovarian carcinoma
non invasive in vivo imaging of the differentially expressed tumor associated antigen PSMA by a specific Positron Emission Tomography (PET) ligand
209
a highly selective IDO1 inhibitor that shows good in vivo efficacy in
combination with immune checkpoint inhibitors, and favorable predicted human
pharmacokinetic properties
210
Suarez-Carmona-
211
Thierauf-
Checkpoint-Inhibition
Marschall-Protecting
212
Trezise-
Quantitative
193
Menevse-
Discovering
213
van Helden- Rapid
194
Michels-
TiMi1
is a novel immune checkpoint in solid tumors differentially regulating
cAMP-depending signaling in tumor-infiltrating lymphocytes
214
Walter-
Anti-tumor
195
Mitnacht-Kraus-
IMAB362-vcMMAE , a CLDN18.2-specific antibody-drug conjugate, is effective
against human gastric cancer cells in vitro and in vivo
215
Zelba-
In renal
196
Okadayes
Novel
197
Olwill-
Costimulatory
198
Paret-
Immunogenic
199
Pfeiferyes
Sialyl
200
Platzer-
Cytoreductive
201
Posselt-
Targeting
-
immune cells from activation-induced apoptosis via the CD95L-blocking
compound APG101
novel targets in a high-throughput fashion: RNAi screen for pancreatic
ductal adenocarcinoma (PDAC) associated immune modulators
-
Ovarian carcinoma explant culture: model development and application in drug
testing
for advanced mucosal melanoma
live-cell imaging assays for immunotherapy: chemotaxis, T-cell killing
& phagocytosis
generation of T cell receptor like antibodies using genetically reprogrammed
memory B cells of immunized rabbits
activity of IMAB027 antibody as a single agent and in combination with
chemotherapy in testicular cancer
cell and prostate cancer a large fraction of the tumor-infiltrated T-cells cannot be targeted by current checkpoint inhibition approaches
and shared neoantigen for glioma T cell therapy derived from histone 3 variant H3.3 K27M mutation
T-cell engagement by the CD137/HER2 bispecific, PRS-343, leads to
anti-tumor effect and increased tumor infiltrating lymphocytes in a humanized
mouse model
lipids of pediatric brain cancer
Glycolipid Stage-Specific Embryonic Antigen 4 (SSEA4) – a novel target for
CAR T cell therapy of solid cancers
and Immunmodulatory drugs influence bispecific CD33/CD3 BiTE®
antibody construct (AMG 330) mediated cytotoxicity against Acute Myeloid Leukemia (AML)
DNA damage response genes to improve radiotherapy of pancreatic can-
cer
202
Ramskov-
Evaluating
203
Riemer-
Evaluation
204
Ruzicka-
Immunotherapy
205
Schnieders-4-1BBL
56
prediction strategies for identification of immunogenic mutation-derived
neo-epitopes in melanoma
of T cell epitope prediction servers
targeting RIG-I in a mouse model of acute myeloid leukemia
synergizes with IL-12 and IL-2 in the induction of a defensive immune signature in the human urinary bladder carcinoma microenvironment
57
CIMT Abstracts
CIMT Abstracts
Improving Immunity
Improving Immunity
No.:
Title:
No.:
Presenter: 216
Second
Beha-
217
Bou Nasser Eddine-
218
Buonaguro-Effects
219
Clemenz-
Dermaject
generation of IL-15-based tri-functional antibody fusion proteins with
costimulatory TNF-superfamily ligands for cancer therapy
234
Parviainen-TNFa
Optimal triggering of anti-tumor CD4+ TH cells by tumor cells expressing CIITAdriven MHC class II I-A-only molecules
235
Rekdal-
The
of RNA-based RNAdjuvant® on PBMCs from liver cancer patients in an ex
vivo model
236
Richardsyes
Hexavalent
237
Sanders-
Immunological,
238
Sapski-
Combinatorial
239
Spagnuolo-Modulation
– a novel, convenient intradermal injection device for intracutaneous
Shor t talk:
and IL-2 armed oncolytic adenovirus induces antitumor immune response
and protects from tumor rechallenge in Syrian hamsters
oncolytic peptide LTX-315 enhances T cell clonality and induces synergy with
CTLA-4 blockade
agonists targeting receptors of the tumor necrosis factor superfamily:
TRAIL, CD40L, CD27L and beyond
anti-angiogenic and clinical effects of intratumoral interleukin-12
electrogene therapy plus metronomic cyclophosphamide in dogs with spontaneous
cancer
injections
220
221
checkpoint blockade enhances anti-tumor activity of CEA TCB, a novel T-cell
bispecific antibody for the treatment of solid tumors
ColombettiyesPD-L1
an oncolytic herpes viroimmunotherapeutic, enhances therapeutic efficacy of T cell checkpoint inhibition in solid tumors by increasing T cell recruitment
and remodeling the immunosuppressive microenvironment
approaches with costimulatory antibody fusion proteins addressing
immunosuppression by IL-10, TGF-beta and immune checkpoints
Cripeyes
Seprehvir,
222
de Gruijlyes
Local
adjuvant treatment of clinical stage I-II melanoma with CpG-B/GM-CSF
improves distant recurrence-free survival: long-term follow-up of three randomized
controlled phase II trials
223
Donnellan-IMCgp100
224
Eissleryes
Release
225
Holland-
Comparison
226
Hotz-
Reprogramming
ImmTAC: A TCR-based bi-specific immunotherapy for the treatment of
advanced melanoma
of IFN-γ induced chemokines provides the key to efficient combination immunotherapy of anti-PD-1 antibody with CSF-1R inhibitor
of phase I/II trials regarding antigen-specific versus non-specific anticancer immunotherapies
of TLR7 signaling enhances antitumor NK and cytotoxic T cell
Title:
of T cell recruitment into tumors through synergy between HMGB1 and
CXCL12
Efficacy of a novel multi-drug metronomic chemotherapy combined with a peptide
vaccine on tumor challenge in mice
240
Tagliamonte-
241
Tähtinen-
T-cell
242
Theurich-
Local
243
Tognarelli-NK
244
Zhu-
Combination
therapy enabling adenoviruses coding for IL-2 and TNF-a systematically activate tumor-reactive TILs in metastatic, solid cancer
tumor treatment in combination with systemic ipilimumab immunotherapy
prolongs overall survival in patients with advanced malignant melanoma
cell characteristics and anti-tumor efficacy in multiple myeloma and lymphoma
patients before and after autologous stem cell transplantation
immunotherapy of an inducible, autochthonous, low mutational load
murine lung cancer model expressing human CEA as a tumor-associated self-antigen
responses
227
Kapp-
In vitro
and in vivo evaluation of the TLR9 agonist EnanDIM for cancer immuno-
therapy
228
Kayali-
Platelet-derived
229
Kikodze-
Influence
230
Koksal-
Memory-like
231
Kwekkeboomyes
Functionality of tumor-infiltrating T cells in hepatocellular carcinoma can be enhanced by blocking several co-inhibitory pathways
232
Kwekkeboom-
Blocking PD-L1 and LAG-3 can revitalize the functionality of tumor-infiltrating T
cells in liver metastasis from colorectal cancer
233
O'Donnell-
Probing
58
microparticles differentially regulates macrophage polarization
of radiofrequency thermal ablation on CD4+ T cell subsets in the patients with liver cancer
T cells transduced with tumor-specific epitope elicited pronounced
cytotoxic potential
the increase in neoantigen burden at recurrence in ovarian cancer
59
CIMT Abstracts
CIMT Abstracts
Tumor Biology and Interaction with the Immune System
No.:
Presenter: 245
TRPV1
Akman-
246
Al Absi-
Actin
247
248
249
250
Shor t talk:
Title:
and TrkA agonists alter cytokine secretions of mix leukocyte cultures obtained from tumor-bearing mice
cytoskeleton remodeling: a novel mechanism for tumor cells to escape from
natural killer cell-mediated cell death
tolerance transforms tumor antigen specific naive CD4 T cells into
induced Tregs in a spontaneous lung tumor model
No.:
Presenter: 264
The effects
Erin-
265
Erin-
Inhibition
266
Erin-
Effects
267
Fernandes-Characterization
Alonsoyes
"Infectious"
Arakelian-
Hypoxia
in the tumor microenvironment: A major regulator of the anti-tumor immune response
macrophage phenotype makes low grade ovarian cancer a possible target for immunotherapy
of PKC activity with Byrostatin alters secretion of inflammatory
chemokines
of phosphoramidon on TNF-a and IFN-g release from mix leukocyte culture
obtained from tumor-bearing mice
of the immunogenicity of pancreatic cells in response to electro-
Fischer-
Tumor-infiltrating
269
Fischer-
Bifunctional
270
Foerster-
The
271
Foerster-
Allogeneic
272
Forlani-
Block
273
Furnessyes
Characterisation
role of local immune infiltrate in patients with colon cancer
274
Gabriele-
On-chip
of MHC class I and class II deficient tumor cell lines using the CRISPR/
Cas9 system
275
Georganaki- Sunitinib
276
Gorris-
Development
277
Hassel-
Investigation
278
Hu-
Role of
279
Kienzle-
Targeting
280
Kim-
A novel
281
Knott-
Tumor-derived
Berthel-
Spatial
heterogeneity of T cell distribution patterns at the invasive margin of colorectal cancer liver metastases
T cell costimulatory pathways are required for cisplatin-based chemotherapy
252
Bjerregaard-
MuPeXI: A tool for prediction of neo-epitopes from tumor sequencing data
253
Blattner-
The
254
Boegel-
Determination
255
Buoncervello-
256
Calvo-
Prognostic
257
Das-
Generation
role of CCR5 on MDSC in their recruitment and activation in melanoma microenvironment
of HLA type and expression from whole transcriptome sequencing
data (RNA-Seq)
IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic
drugs on both metastatic and stem cells of colorectal cancer
258
de Bruyn-
Treatment
259
Dekenyes
Synergy
regimen, surgical outcome and T cell differentiation influence prognostic
benefit of tumor-infiltrating lymphocytes in high grade serous ovarian cancer
of anti-PD-1 in combination with targeted therapy is mediated by CD8+ T
cells
260
Dosset-
PD-L1
261
Eggink-
POLE
60
of PU-H71, a novel HSP90 inhibitor, and radiotherapy co-treatment in
metastatic breast carcinoma: Changes in IL-6 and macrophage inflammatory protein 2
268
Beyranvand Nejad-
263
Title:
chemotherapy
Baert-
Tumour-associated
251
262
Shor t talk:
tumor expression as an adaptive immune resistance mechanism to counter
the antitumor effect of immunogenic chemotherapies
proofreading domain mutations elicit an antitumor immune response in
endometrial cancer
Elkord-
GARP/LAP
expression on FoxP3+/-Helios+/- Treg subsets in patients with pancreatic cancer and liver metastases from colorectal cancer
Erin-
CD200
mimetic PEG-M49 increases therapeutic effects of pegylated liposomal doxorubicin on poorly differentiated breast carcinoma: Possible role of in-vivo increased
anti-tumoral immune response
B lymphocytes independently predict outcome in patients with
non-small cell lung cancer and consist mostly of effector subsets
peptide-MHC class I antibody fusions redirect peptide-specific CD8+
T cells to eliminate tumor cells in vivo
immunome of hepatocellular carcinoma – an in silico analysis
Balb/c mice are more susceptible to B16F10 liver metastasis than syngeneic C57/Bl6 mice despite a M1-polarized anti-tumor immune response
of the HTLV-1 Tax-1 oncogene-dependent NF-kB activation by the MHC class
II transactivator CIITA. Implications for the control of oncogenic potential of HTLV1 infection
of immune and tumour-specific neoantigen landscapes informs
optimal therapeutic targeting in non-small cell lung cancer
dialogue between immune cells and cancer: tracking human dendritic cell
migration and tumor antigen capture upon drug treatment
enhances the anti-tumor responses of agonistic CD40-antibody therapy
by reducing MDSCs and synergistically improving endothelial activation and T-cell
recruitment
of multiplex fluorescent IHC immune cell panels to predict immunotherapy outcome
of tumor-reactive T-cell repertoire in the immune infiltrate of metastatic melanoma under immune checkpoint inhibition
tumor-derived exosomes in immunosuppression in malignant melanoma
Cancer: Encapsulation of TNF-α in pH-sensitive PEI-PEG copolymer gated
dendritic mesoporous silica nanoparticle
model of murine hepatocarcinogenesis in biliary fibrotic mice resembling
the multistage process of human primary liver cancer
IL-1 mediates intratumoral immunosuppression via the Treg-attracting chemokine CCL22
61
CIMT Abstracts
CIMT Abstracts
No.:
Presenter: 282
Shor t talk:
Title:
No.:
Presenter: Escape
Koch-
301
Increased
Qureshi-
283
Komdeur-
CD103
302
Ramjiawanyescxcr4
284
Konkol-
Presence
of immune infiltrates in early phases of prostate cancer: Development of a
preclinical efficacy model to promote immunotherapy development
303
Röhle-
Characterization
PD-L1, Galectin-9 and CD8+ TIL are associated with patient survival in Hepatocellular Carcinoma
304
Sainiyes
Identification
vivo high-throughput T cell receptor profiling of a melanoma patient’s peripheral tumor antigen-specific T cell repertoire
305
Sapega-
IL-12
Patient-derived tumor xenografts in humanized NSG and NSG-SGM3 mice: A model
to study immune responses in cancer therapy
306
Sauer-
HLA
307
Schmidt-
Tumor
308
Schotte-
A patient
of head and neck squamous cell carcinoma from NKG2D-dependent NK cell
immunosurveillance can be restored by NKG2D ligand depletion
defines intraepithelial CD8+ PD1+ tumor-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma
Shor t talk:
Title:
CD4+ and CD8+ lymphocytic infiltration in patients with triple negative
breast cancer suggests susceptibility to immune therapy
inhibition in tumor microenvironment facilitates anti-program death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice
and characterization of neoepitopes associated with individual mutational landscape in non-small cell lung cancer
285
Kwekkeboom-
286
Lennerz-
Ex
287
Low-Marchelli-
288
Marcq-
Into
289
Metzger-
Surface
290
Momose-
Identification
309
Schrörs-
Complex
291
Mullins-
A Crohn´s
related colonic carcinoma cell line showing features of immunoselection
is recognized by re-activated autologous tumor-infiltrating lymphocytes as well as
CIK cells
310
Schupp-
Activating
292
Nesmiyanov-
mIRNA-155 shuttling through gap junctions facilitates CLL progression
311
Seo-
The role
293
Ozdemir-
Investigation
312
Shatnyeva-BAG6
313
Siozopoulou-
the deep: closer look at immune cells and immune checkpoint expression in
human malignant pleural mesothelioma
staining of PD-1 discriminates viable cell populations
of cytotoxic miRNAs in human T cell-released exosomes against mesenchymal stem cells
of paracrine immunomodulatory effects of mesenchymal stem cells
on the CD4+ T cell subsets
The immunohistochemical investigation of CD44, CD133, NANOG, OCT 3/4, HLA-G
and HLA expressions in the advanced stage breast cancer
therapy suppresses TC-1 tumor growth accelerated by admixture of the
docetaxel-treated senescent tumor cells
class II antigen expression in cervical intraepithelial neoplasia and invasive
cancer
and host cell PD-L1 expression is required to mediate suppression of antitumor immunity
derived antibody targeting CD9 inhibits melanoma metastasis
deletion event at B2M locus in a human melanoma patient treated with
IVAC MUTANOME
and repolarizing immune suppressive tumor associated macrophages
using siRNA encapsulated in nano-sized carriers to initiate an anti-tumor immune
response against melanoma
of CD8+ T cell-released exosomes on the down-regulation of tumor invasion and metastasis by elimination of stromal mesenchymal cells
and CBP/p300 regulate ESCRT-mediated exosomes release and protein sorting
Desmoid tumors: the importance of the immune cell determination to the development of new treatment options
294
Özgül Özdemir-
295
Park-
Evaluation
314
Skadborg-
Characterization
296
Parri-
Identifying
315
Solinas-
Characterization
297
Parrot-
CD40L+CD4+CD8+
316
Sonner-
No
317
Steinhoff-
PD-L1
318
Stoitzner-
Cooperation
319
Tanriover-
The
of potential factors contributing to immunosuppression in the PDL1
positive tumor microenvironment
the kinases and phosphatases regulating STAT3 with potential dual
anti-cancer and immunotherapeutic effects
intra-tumor double positive T cells : a helper player in mela-
noma
298
299
Prokopi-
Immune
300
Qureshi-
Characterization
62
-
evasion by melanoma: Modification of the skin and lymph node immune
cell network in a spontaneous melanoma mouse model
of the cancer immune microenvironment of Mdr2(Abcb4)-/- mice
treated with Diethylnitrosamine and Phenobarbital – A novel model close to human
Hepatocracinogenesis
and specificity analysis of tumor infiltrating lymphocytes in ovar-
ian carcinoma
of inhibitory molecules on tumor-infiltrating lymphocytes in malignant melanoma
of PD-L1 and PD-1 expression in tumor infiltrating lymphocytes
and tertiary lymphoid structures in paired primary tumors and metastases from
breast cancer patients
role of the stress kinase GCN2 in T cell-mediated tumor rejection as intratumoral tryptophan levels are maintained
upregulation following RLR and TLR-based immunotherapy in a mouse
model of gastric cancer
of Langerhans cells and NK cells guarding the epidermis during
chemical carcinogenesis
expression of Gr1+ and S100A8/A9+ cells in primary tumors and visceral
organs invaded by breast carcinoma cells
63
CIMT Abstracts
CIMT Abstracts
No.:
Title:
320
Taranikanti- Alteration
321
ten Buren-Genetic
322
Thomé-
Glioma
323
Treder-
Anti-tumor
of host immunity with stress in breast cancer patients
engineering in a non-traditional astrocytoma prone mouse background
N-Myc downstream regulated gene 1 (NDRG1) shapes the tumor microenvironment
efficacy by the bispecific tetravalent CD30/CD16A TandAb AFM13 is
characterized by strong cross-talk from innate to adaptive immunity and is enhanced by immune checkpoint inhibitor anti-PD-1
324
Vascotto-
Induction
of a well-defined immune response using a novel systemically applied
Toll-Like Receptor 7 agonist in mice and men
325
VerdegaalyesA
326
Vetter-
Tolerogenic
327
Voigt-
Impact
328
Wölfl-
A dual
changing neo-antigen landscape in human melanoma under T cell pressure
effects of GM-CSF through expansion of regulatory T-cells and induction of the Treg-associated chemokine CCL22
of Interleukin-22 on two murine models of lung and breast cancer
role for IL12 in T-cell receptor-dependent and –independent tumor cell
killing: regulation of a DNAM1 mediated, PTPRC/CD45-dependent mechanism in
human effector T-cells
Patient-derived tumor xenografts in humanized mice: a preclinical model for the
development of innovative immunotherapeutics
329
Wulf-Goldenberg-
330
Zayoud-
The
331
Zhao-
Genetic
role of the IL-22/IL-22R1 axis in Pancreatic ductal adenocarcinoma
heterogeneity of intra-patient metastases restricts T-cell recognition of malignant melanoma
[ A ] Akman. . . . . . . . . . . . . 245
Al Absi. . . . . . . . . . . . . 246
Allagui. . . . . . . . . . . . . 001
Allard. . . . . . . . . . . . . . 075
Alonso. . . . . . . . . . . . . 247
Amann. . . . . . . . . . . . . 076
Andersen. . . . . . . . . . 139
Angerer. . . . . . . . . . . . 002
Arakelian . . . . . . . . . . 248
Ashfield. . . . . . . . . . . . 167
Audehm . . . . . . . . . . . 077
Aurisicchio. . . . . . . . . 003
Ayers. . . . . . . . . . . . . . 168
[ B ] Baert. . . . . . . . . . . . . . 004
Baert. . . . . . . . . . . . . . 249
Banki. . . . . . . . . . . . . . 005
Bassani-Sternberg. 169
Beck. . . . . . . . . . . . . . . 170
Beha . . . . . . . . . . . . . . 216
Bekeschus. . . . . . . . . 171
Bentzen . . . . . . . . . . . 140
Berger. . . . . . . . . . . . . 078
Berthel . . . . . . . . . . . . 250
Beyranvand Nejad . . 251
Bialkowski. . . . . . . . . 006
Bianchi . . . . . . . . . . . . 079
Bigalke . . . . . . . . . . . . 007
Bjerregaard. . . . . . . . 252
Blattner. . . . . . . . . . . . 253
Boegel. . . . . . . . . . . . . 254
Bonte. . . . . . . . . . . . . . 080
Bou Nasser Eddine. . 217
Braitbard . . . . . . . . . . 172
Bräunlein. . . . . . . . . . 173
Brey. . . . . . . . . . . . . . . 081
Buettner. . . . . . . . . . . 174
Bulgarelli . . . . . . . . . . 009
Bunse . . . . . . . . . . . . . 010
Buonaguro. . . . . . . . . 011
Buonaguro. . . . . . . . . 218
Buoncervello. . . . . . . 255
[ C ] Calvo. . . . . . . . . . . . . . 256
Campillo-Davo. . . . . 082
Capasso. . . . . . . . . . . 012
Cappuzzello. . . . . . . . 083
Cebula. . . . . . . . . . . . . 013
Challis. . . . . . . . . . . . . 141
Chandran. . . . . . . . . . 142
Chaperot. . . . . . . . . . . 084
Charpentier. . . . . . . . 175
Chiang. . . . . . . . . . . . . 143
Clemenz. . . . . . . . . . . 219
Colombetti. . . . . . . . . 220
Conner. . . . . . . . . . . . . 014
Coosemans. . . . . . . . 144
Cripe. . . . . . . . . . . . . . . 085
Cripe. . . . . . . . . . . . . . . 221
[ D ] Dal Col. . . . . . . . . . . . . 016
Das. . . . . . . . . . . . . . . . 257
de Bruyn. . . . . . . . . . . 258
64
de Goeje. . . . . . . . . . . 145
de Gruijl. . . . . . . . . . . . 222
de Haar. . . . . . . . . . . . 017
de Koning. . . . . . . . . . 146
Deiser. . . . . . . . . . . . . 018
Deken . . . . . . . . . . . . . 259
Deumelandt . . . . . . . 176
Dewitte. . . . . . . . . . . . 019
Di Marco. . . . . . . . . . . 177
Donnellan. . . . . . . . . . 223
Doorduijn. . . . . . . . . . 178
Doorduijn. . . . . . . . . . 179
Dorer. . . . . . . . . . . . . . 020
Dörrie. . . . . . . . . . . . . . 021
Dosset. . . . . . . . . . . . . 260
Dutoit . . . . . . . . . . . . . 086
Hooijberg. . . . . . . . . . 036
Hotz. . . . . . . . . . . . . . . 226
Hoyer. . . . . . . . . . . . . . 037
Hu. . . . . . . . . . . . . . . . . 278
[ I ] Ilecka. . . . . . . . . . . . . . 181
Inderberg. . . . . . . . . . 093
[ J ] Jabulowsky . . . . . . . . 038
Jamitzky. . . . . . . . . . . 094
Janssen. . . . . . . . . . . . 095
Jin. . . . . . . . . . . . . . . . . 096
[ E ] Eggink. . . . . . . . . . . . . 261
Eissler. . . . . . . . . . . . . 224
Elkord . . . . . . . . . . . . . 262
Erin. . . . . . . . . . . . . . . . 263
Erin. . . . . . . . . . . . . . . . 264
Erin. . . . . . . . . . . . . . . . 265
Erin. . . . . . . . . . . . . . . . 266
Eyrich. . . . . . . . . . . . . . 022
Eyrich. . . . . . . . . . . . . . 023
[ F ] Fåne. . . . . . . . . . . . . . . 087
Feger. . . . . . . . . . . . . . 024
Fernandes. . . . . . . . . 267
Fischer . . . . . . . . . . . . 268
Fischer . . . . . . . . . . . . 269
Foerster. . . . . . . . . . . 270
Foerster. . . . . . . . . . . 271
Forlani. . . . . . . . . . . . . 272
Fotaki. . . . . . . . . . . . . . 025
Friese. . . . . . . . . . . . . . 088
Frøsig. . . . . . . . . . . . . . 026
Furness. . . . . . . . . . . . 273
[ G ] Gabriele. . . . . . . . . . . . 274
Galaine . . . . . . . . . . . . 147
Gary. . . . . . . . . . . . . . . 089
Gaudernack. . . . . . . . 027
Georganaki. . . . . . . . . 275
Gerer. . . . . . . . . . . . . . 028
Gomez-Eerland. . . . 090
Gorris. . . . . . . . . . . . . . 276
Gouttefangeas. . . . . 148
Grees. . . . . . . . . . . . . . 029
Grenov. . . . . . . . . . . . . 030
[ H ] Halldórsdóttir. . . . . . 180
Hammerich. . . . . . . . 031
Harada . . . . . . . . . . . . 032
Hassel. . . . . . . . . . . . . 277
Heidenreich. . . . . . . . 033
Hillerdal. . . . . . . . . . . . 091
Hodgins . . . . . . . . . . . 092
Høgset . . . . . . . . . . . . 034
Holland. . . . . . . . . . . . 225
Holmberg. . . . . . . . . . 035
[ K ] Kapp. . . . . . . . . . . . . . . 227
Kayali. . . . . . . . . . . . . . 228
Kayser. . . . . . . . . . . . . 097
Kedde . . . . . . . . . . . . . 182
Kienzle. . . . . . . . . . . . . 279
Kikodze. . . . . . . . . . . . 229
Kim. . . . . . . . . . . . . . . . 280
Kirkin. . . . . . . . . . . . . . 098
Klaver . . . . . . . . . . . . . 099
Knott. . . . . . . . . . . . . . 281
Koch. . . . . . . . . . . . . . . 282
Koksal. . . . . . . . . . . . . 230
Komdeur. . . . . . . . . . . 283
Konkol. . . . . . . . . . . . . 284
Krächan. . . . . . . . . . . . 183
Kramer . . . . . . . . . . . . 039
Kraus. . . . . . . . . . . . . . 100
Krebs. . . . . . . . . . . . . . 149
Kremer . . . . . . . . . . . . 101
Kreuzberg. . . . . . . . . . 185
Kunert. . . . . . . . . . . . . 102
Kunert. . . . . . . . . . . . . 103
Kuttruff-Coqui . . . . . 040
Kwekkeboom . . . . . . 186
Kwekkeboom . . . . . . 231
Kwekkeboom . . . . . . 232
Kwekkeboom . . . . . . 285
Kyzirakos. . . . . . . . . . 041
[ L ] Lameris. . . . . . . . . . . . 104
Lee. . . . . . . . . . . . . . . . 187
Legscha. . . . . . . . . . . . 105
Lennerz. . . . . . . . . . . . 286
Leon. . . . . . . . . . . . . . . 188
Leon. . . . . . . . . . . . . . . 189
Lichty. . . . . . . . . . . . . . 042
Löffler. . . . . . . . . . . . . 043
Low-Marchelli. . . . . . 287
Lybaert. . . . . . . . . . . . 044
Lyngaa. . . . . . . . . . . . . 150
[ M ] MacLeod. . . . . . . . . . . 106
Mall . . . . . . . . . . . . . . . 107
Mandruzzato. . . . . . . 151
Marcq . . . . . . . . . . . . . 288
Marillier. . . . . . . . . . . . 190
Marschall. . . . . . . . . . 192
Mazorra . . . . . . . . . . . 045
McCreedy. . . . . . . . . . 108
Menevse. . . . . . . . . . . 193
Mensali. . . . . . . . . . . . 109
Metzger . . . . . . . . . . . 289
Michels. . . . . . . . . . . . 194
Mikyšková. . . . . . . . . 046
Miller. . . . . . . . . . . . . . 047
Mitnacht-Kraus. . . . 195
Moise. . . . . . . . . . . . . . 048
Momose. . . . . . . . . . . 290
Montico. . . . . . . . . . . . 049
Mottas . . . . . . . . . . . . 050
Mroz. . . . . . . . . . . . . . . 110
Müller . . . . . . . . . . . . . 051
Mullins . . . . . . . . . . . . 291
[ N ] Nair . . . . . . . . . . . . . . . 052
Nelde. . . . . . . . . . . . . . 053
Nesmiyanov . . . . . . . 292
Niedermann . . . . . . . 152
[ O ] O'Donnell. . . . . . . . . . 233
Oberoi. . . . . . . . . . . . . 111
Okada . . . . . . . . . . . . . 196
Olwill. . . . . . . . . . . . . . 197
Omokoko. . . . . . . . . . 153
Orlinger. . . . . . . . . . . . 054
Owens. . . . . . . . . . . . . 113
Ozdemir. . . . . . . . . . . 293
Özgül Özdemir. . . . . 294
[ P ] Paret. . . . . . . . . . . . . . 198
Park. . . . . . . . . . . . . . . 295
Parri. . . . . . . . . . . . . . . 296
Parrot . . . . . . . . . . . . . 297
Parviainen. . . . . . . . . 234
Peper. . . . . . . . . . . . . . 154
Peres. . . . . . . . . . . . . . 055
Pfeifer. . . . . . . . . . . . . 199
Pfeiffer. . . . . . . . . . . . 114
Platzer. . . . . . . . . . . . . 200
Podola. . . . . . . . . . . . . 056
Podrazil. . . . . . . . . . . . 057
Posselt. . . . . . . . . . . . 201
Prokopi. . . . . . . . . . . . 299
[ Q ] Qureshi. . . . . . . . . . . . 300
Qureshi. . . . . . . . . . . . 301
[ R ] Rabsteyn. . . . . . . . . . 058
Rabu . . . . . . . . . . . . . . 059
Raemdonck. . . . . . . . 115
Ramachandran. . . . . 060
Ramjiawan. . . . . . . . . 302
Rammensee. . . . . . . 061
Ramskov . . . . . . . . . . 202
Rataj . . . . . . . . . . . . . . 117
Rathinasamy. . . . . . . 155
Rekdal. . . . . . . . . . . . . 235
Richards. . . . . . . . . . . 236
Riemer . . . . . . . . . . . . 203
Rodrigues-Santos. . . 156
Röhle. . . . . . . . . . . . . . 303
Rothe. . . . . . . . . . . . . . 063
Ruzicka. . . . . . . . . . . . 204
[ U ] [ S ] Van Acker. . . . . . . . . . 069
Van der Jeught. . . . . 070
van Helden. . . . . . . . . 213
Vascotto. . . . . . . . . . . 324
Verbeke. . . . . . . . . . . . 071
Verdegaal. . . . . . . . . . 325
Vetter . . . . . . . . . . . . . 326
Vigano. . . . . . . . . . . . . 162
Voigt. . . . . . . . . . . . . . . 327
Vormehr. . . . . . . . . . . 072
Voss. . . . . . . . . . . . . . . 133
Saini. . . . . . . . . . . . . . . 304
Sainz. . . . . . . . . . . . . . 064
Sanders. . . . . . . . . . . . 065
Sanders. . . . . . . . . . . . 237
Sandri . . . . . . . . . . . . . 118
Sapega . . . . . . . . . . . . 305
Sapski. . . . . . . . . . . . . 238
Sauer. . . . . . . . . . . . . . 306
Schaft. . . . . . . . . . . . . 119
Schmidt. . . . . . . . . . . . 157
Schmidt. . . . . . . . . . . . 307
Schnieders. . . . . . . . . 205
Schoor. . . . . . . . . . . . . 120
Schörg. . . . . . . . . . . . . 121
Schotte. . . . . . . . . . . . 308
Schrörs. . . . . . . . . . . . 309
Schupp . . . . . . . . . . . . 310
Schuster. . . . . . . . . . . 206
Schütt. . . . . . . . . . . . . 122
Schütz. . . . . . . . . . . . . 066
Schütz. . . . . . . . . . . . . 123
Schwenck. . . . . . . . . . 207
Seo. . . . . . . . . . . . . . . . 311
Seth. . . . . . . . . . . . . . . 067
Shatnyeva. . . . . . . . . 312
Shuttleworth. . . . . . . 208
Simon . . . . . . . . . . . . . 124
Simon . . . . . . . . . . . . . 158
Singh. . . . . . . . . . . . . . 125
Siozopoulou. . . . . . . . 313
Skadborg . . . . . . . . . . 314
Solinas. . . . . . . . . . . . . 315
Solum . . . . . . . . . . . . . 126
Sonner. . . . . . . . . . . . . 316
Spagnuolo. . . . . . . . . 239
Stam . . . . . . . . . . . . . . 159
Steinhoff. . . . . . . . . . . 317
Stoitzner. . . . . . . . . . . 318
Suarez-Carmona. . . 210
Such. . . . . . . . . . . . . . . 128
Urbiola. . . . . . . . . . . . . 068
Uslu. . . . . . . . . . . . . . . 132
[ V ] [ W ] Wälchli. . . . . . . . . . . . . 134
Walter. . . . . . . . . . . . . 214
Weinstein-Marom. . . 135
Welters. . . . . . . . . . . . 163
Welters. . . . . . . . . . . . 164
Wennhold. . . . . . . . . . 136
Westergaard. . . . . . . 137
Wistuba-Hamprecht . 165
Wölfl . . . . . . . . . . . . . . 328
Wollmann. . . . . . . . . . 073
Wulf-Goldenberg. . . 329
[ Y ] Yang. . . . . . . . . . . . . . . 074
[ Z ] Zayoud . . . . . . . . . . . . 330
Zelba. . . . . . . . . . . . . . 215
Zelle-Rieser. . . . . . . . 166
Zhang . . . . . . . . . . . . . 138
Zhao. . . . . . . . . . . . . . . 331
Zhu. . . . . . . . . . . . . . . . 244
[ T ] Taborska. . . . . . . . . . . 129
Tagliamonte. . . . . . . . 240
Tähtinen. . . . . . . . . . . 241
Tanriover. . . . . . . . . . . 319
Taranikanti. . . . . . . . . 320
ten Buren. . . . . . . . . . 321
Theurich. . . . . . . . . . . 242
Thierauf . . . . . . . . . . . 211
Thomé. . . . . . . . . . . . . 322
Tognarelli. . . . . . . . . . 243
Tosi. . . . . . . . . . . . . . . . 130
Treder . . . . . . . . . . . . . 323
Trezise. . . . . . . . . . . . . 212
Tubb. . . . . . . . . . . . . . . 131
Tudor. . . . . . . . . . . . . . 160
Turksma. . . . . . . . . . . 161
65
CRI-CIMT-EATI-AACR
SECOND INTERNATIONAL
CANCER IMMUNOTHERAPY
CONFERENCE
TRANSLATING
SCIENCE INTO
SURVIVAL
September 25-28, 2016
Sheraton New York Times Square Hotel
New York, NY
Submit an Abstract By: Thursday, June 16, 2016
Register and Save By: Monday, August 8, 2016
CONFERENCE CO-CHAIRPERSONS
James P. Allison
The University of Texas MD Anderson Cancer
Center, Houston, TX
Christoph Huber
Association for Cancer Immunotherapy
(CIMT), Mainz, Germany
Philip D. Greenberg
Fred Hutchinson Cancer Research Center
and University of Washington, Seattle, WA
Guido Kroemer
Institut Gustave Roussy,
Villejuif, France
ABOUT THIS CONFERENCE
The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor
Immunology (EATI), and the American Association for Cancer Research (AACR) are proud to once again join forces
to present the International Cancer Immunotherapy Conference. The program will focus on “Translating Science into
Survival” and feature talks from more than 60 leaders in the field covering all areas of inquiry in cancer immunology
and immunotherapy. This meeting will provide an unparalleled opportunity for teaching, learning, and networking
among all stakeholders in the field: scientists, clinicians, regulators, drug developers, and patient advocates.
Continuing Medical Education (CME) Activity–AMA PRA Category 1 CreditsTM available
Learn more at CancerImmunotherapyConference.org
ANNUAL MEETING
MEET AND
EAT IN MAINZ
Interested in meeting other out-of-town conference participants
for dinner? Sign up for a dinner group on May 10 at one of several
restaurants in Mainz.
For more information, come to the registration desk. Deadline for
sign-up is May 10, at 3 p.m..
Imprint
POSTAL ADDRESS
CIMT - Association for Cancer Immunotherapy
Hölderlinstraße 8
Telephone: +49 (0) 6131 - 55 47 40 0
Website: www.cimt.eu
E-Mail: office@cimt.eu
REGISTER OF ASSOCIATIONS
Amtsgericht Mainz: VR 3783
CONCEPT AND DESIGN
LABOR − Agentur für moderne Kommunikation GmbH
Fischtorplatz 21
Telephone: +49 (0) 6131 - 30 46 76 2
Website: www.labor.digital
PHOTOS
Andrea Enderlein
© Immunologische Krebs-Therapie e.V. (Association for Cancer Immunotherapy). All rights reserved.
We gratefully acknowledge the support from our sponsors.
Platinum
Gold
Silver
Bronze
Partners
Smartphone Schedule
Get the CIMT online schedule
for your smartphone
schedule.cimt.eu
Online Abstracts
Get the CIMT online abstracts
(iPad App, eBook, PDF)
abstracts.cimt.eu
find us on facebook
facebook.com/cimtmainz
follow us on twitter
twitter.com/C_IMT
follow us on Linkedin
linkedin.com/company/cimt

the printed Meeting Program

Transcription

Similar documents

The Immunity Boosters - Roswell Park Cancer Institute

Measurement

Feel Your Best with the BOOM!

Allergy Partners Flyer

Exsanguination - Northern Health

AMPULLA OF VATER STAGING FORM

/ Print JoH_Poster_2016 - Fox Valley Brain Tumor Coalition

PATHOLOGY OF SKIN TUMORS

Concept of oncolytic virotherapy- clinical implementation

angionesesis emt metastasis